Document:

Option Agreement dated November 25,2003

 Exhibit 10.33 
  
  
 Portions of this exhibit were omitted and filed separately with the Secretary of the
Commission pursuant to an application for confidential treatment filed with the Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934. Such portions are marked by a series of asterisks. 
  
  
  
  
  
  
  
  
  
  
 OPTION AGREEMENT 
  
  
  
  
 between 
  
  
  
  
 SCHERING CORPORATION 
  
  
  
  
 and 
  
  
  
 VIROPHARMA INCORPORATED 
  

 OPTION AGREEMENT 
  
 This OPTION AGREEMENT (“Agreement”) is made effective as of the latest date of signature appearing below (the “Effective
Date”) by and between Schering Corporation, a New Jersey corporation having its principal place of business at 2000 Galloping Hill Road, Kenilworth, New Jersey 07033 (hereinafter “Schering”) and ViroPharma Incorporated, a Delaware
corporation having offices at 405 Eagleview Boulevard, Exton, Pennsylvania 19341 (hereinafter “ViroPharma”). References to Schering shall include its Affiliates (as hereinafter defined). Each of Schering and ViroPharma are also referred to
herein individually as a “Party” or collectively as the “Parties”. 
  
 WHEREAS, ViroPharma is developing pharmaceutical products containing the Compound (as defined below) for distribution and sale in the Territory (as defined below); and 
  
 WHEREAS, Schering has expertise and experience in the development and commercialization of pharmaceutical products in the Territory; and

  
 WHEREAS, Schering wishes to obtain, and ViroPharma is willing to grant to
Schering, an exclusive option to obtain an exclusive license to pharmaceutical products containing the Compound in the Territory, 
  
 NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants herein contained, the Parties hereto agree as follows: 
  
 1.     DEFINITIONS. 
  
 As used in this Agreement, the following capitalized terms, whether used in the singular or
plural, shall have the respective meanings set forth below: 
  
 1.1     “Affiliate” shall mean either a corporation or other business entity, whether de jure or de facto, which, directly or indirectly, is owned by or is under common ownership with a Party hereto to the
extent of at least fifty percent (50%) of the equity (or such lesser percentage which is the maximum allowed to be owned by a foreign corporation in a particular jurisdiction) having the power to vote on or direct the affairs of the entity and any
person, firm partnership, corporation or other entity actually controlled by, controlling or under common control with a Party to this Agreement. For purposes of clarity and avoidance of doubt, the Parties acknowledge and agree that the existing
joint venture between Merck & Co., Inc. and Schering-Plough Corporation (the corporate parent of Schering) for cholesterol products shall not be deemed an Affiliate of Schering for purposes of this Agreement. 
  
 1.2     “Compound” shall mean the novel
antiviral compound known as pleconaril (also known as VP 63843), as described in U.S. Patent No. 5,464,848, and shall include any stereoisomer, salt, hydrate or crystalline structure thereof. 

 1.3     “Confidential Information” shall mean the Know-How and all other
developments, techniques, methods, materials, reagents, processes, procedures, data, results, conclusions, apparatus, products, trade secrets or other proprietary information or materials, improvements thereto, modifications thereof and know-how,
whether patentable or not, which are disclosed by one Party to the other Party, (a) during discussions or negotiations in connection with this Agreement (including, without limitation, the terms of this Agreement), or (b) during the term of this
Agreement. 
  
 1.4     “Field” shall
mean the treatment or prevention of the common cold in human beings caused by a picornavirus infection. 
  
 1.5     “IND” shall mean an investigational new drug application or the equivalent, which is filed by ViroPharma with the
United States Food and Drug Administration (or any successor agency) to obtain approval to conduct clinical studies in the Field in the United States through administration of the Compound and/or Products to human beings, as well as any
corresponding applications or approvals for the Compound and/or Products in Canada. 
  
 1.6     “Initial Studies” shall mean the following human clinical studies to be performed by ViroPharma using the Compound during the Option Period: (a) a phase I tolerability study; (b)
a phase I F19 MRI study; (c) a phase II dose ranging study, and (d) a phase I CYP 3A drug interaction study, in each case for an intranasal dosage form of the Product. 
  
 1.7     “Know-How” shall mean any and all information, materials, processes and methods owned
by ViroPharma, licensed to ViroPharma under the SaSy Agreement, or otherwise controlled by ViroPharma which during the term of this Agreement are not generally known and are utilized in connection with the development, manufacture or use of the
Compound and/or the Products. 
  
 1.8    
“License Agreement” shall mean the definitive license agreement to be negotiated and entered into by the Parties following the exercise of the Option by Schering and incorporating the terms and conditions set forth in Exhibit A.

  
 1.9     “NDA” shall mean a New
Drug Application, Product License Application or the equivalent, which is filed with the United States Food and Drug Administration (or any successor agency) seeking approval to market and sell a Product in the Field in the United States, as well as
any corresponding applications or approvals for the Product in the Field in Canada. 
  
 1.10     “Negotiation Period” shall mean the ******* period beginning on the Option Exercise Date during which the Parties will finalize and enter into the License Agreement, including as
such period may be extended pursuant to Section 2.6. 
  
 1.11     “Option” shall have the meaning set forth in Section 2.1. 
  
 1.12     “Option Period” shall mean the period beginning on the Effective Date and expiring on the earliest of: 

 

 2 

	 	(a)	 	******* after the date on which Schering receives from ViroPharma the final data and results of the last to be completed of the Initial Studies, including access to, or a copy of
the database of such study in a format mutually agreeable to the Parties, 

  

	 	(b)	 	the Option Exercise Date, or 

  

	 	(c)	 	the date on which Schering notifies ViroPharma in writing that it has no further interest in exercising the Option. 

  
 1.13     “Option Exercise Date” shall mean the
date on which Schering notifies ViroPharma in writing that it is exercising the Option pursuant to Section 2.2. 
  
 1.14     “Patent Rights” shall mean any granted patents and/or pending patent applications related to the development,
manufacture or use of the Compound in the Territory that are owned by ViroPharma, licensed to ViroPharma under the SaSy Agreement, or otherwise controlled by ViroPharma, including any substitutions, divisions, continuations, continuations-in-part,
reissues, renewals, registrations, confirmations, re-examinations, extensions, supplementary protection certificates or the like, or provisional applications of any such patents and patent applications, and any equivalents in the Territory of any of
the above. The Patent Rights shall include, without limitation, U.S. Patent No. 5,464,848, Canadian Patent No. 2,094,012, and any other relevant patents licensed to ViroPharma under the SaSy Agreement. 
  
 1.15     “Product” shall mean any form or
dosage of pharmaceutical composition or preparation in final form for sale by prescription, over-the-counter or any other method which contains as an active ingredient the Compound. 
  
 1.16     “Protocol” shall mean, with respect to each of the Initial Studies, the final
protocol (including the investigator’s brochure, patient informed consent form and other relevant documents) for the conduct of such study. 
  
 1.17     “SaSy Agreement” shall mean the First Amended and Restated Agreement, dated February 27, 2001, between
Sanofi-Synthelabo and ViroPharma Incorporated pursuant to which ViroPharama holds a sole and exclusive license in the Territory under certain of Sanofi-Synthelabo’s patents, patent applications, trademarks and know-how relating to the Compound
and/or the Products. 
  
 1.18    
“Territory” shall mean Canada and the United States (including their territories, possessions and commonwealths). 
  
 1.19     “Third Party” shall mean any individual or entity other than Schering, ViroPharma and their respective Affiliates.

  
 1.20     “ViroPharma Compassionate
Use Indications” shall mean the following compassionate use indications which, as of the Effective Date, are included in one or more of ViroPharma’s active INDs for the Compound: 
  

 3 

	 	(a)	 	Acute myocarditis of presumptive picornaviral origin, 

  

	 	(b)	 	Acute or progressive encephalitis of presumptive picornaviral origin, 

  

	 	(c)	 	Neonatal sepsis of presumptive picornaviral origin, 

  

	 	(d)	 	Evidence of presumptive picornaviral infection in the presence of a primary or secondary immune deficient disorder (e.g., Brutons X-linked agammaglobulinemia, severe combined immune
deficiency, hyper IgM, hypogammaglobulinemia, common variable immune deficiency, bone marrow or organ transplant recipients), and 

  

	 	(e)	 	VAPP, wild-type paralytic poliomyelitis, or other paralytic illness of picornaviral origin. 

  
 2.     OPTION RIGHTS 
  
 2.1       Option Grant. ViroPharma hereby grants to Schering an exclusive option to negotiate and enter into an
agreement granting Schering an exclusive, royalty-bearing license under the Patent Rights and Know-How in the Field in the Territory to make, have made, use, import, export, offer for sale and sell the Compound and Products (the “Option”).
In the case of Patent Rights and Know-How licensed to ViroPharma pursuant to the SaSy Agreement, the license to Schering shall be limited at any time during the term of this Agreement to only those rights received by ViroPharma under the SaSy
Agreement (including as it may be amended), as such rights exist at such time. Such agreement shall be substantially in the form of the License Agreement provided for in Section 2.5. For the sake of clarity, in the case of Patent Rights and Know-How
licensed to ViroPharma pursuant to the SaSy Agreement, the sublicense to Schering shall be to the full extent of the rights licensed to ViroPharma, and ViroPharma shall not reduce such extent by its acts or omissions without the prior written
consent of Schering. 
  
 2.2      
Option Exercise. Schering shall have the right to exercise the Option at any time during the Option Period by providing written notice to ViroPharma to that effect. Schering shall notify ViroPharma in writing on or before the expiration of
the Option Period of its decision on whether or not to exercise the Option. Upon exercising the Option, the Parties shall finalize and enter into the License Agreement during the Negotiation Period as provided in Section 2.5. 
  
 2.3       Option Expiration. If Schering
fails to exercise the Option prior to the end of the Option Period, then upon expiration of the Option Period, Schering’s Option shall expire, in which case Schering shall have no further rights or interests in or to the Compound, Products,
Patent Rights or Know-How, and ViroPharma shall have no further obligation to Schering under this Agreement with respect to the licenses contemplated hereunder. 
  

 

 4 

 2.4       Standstill. 
  

	 	(a)	 	Field. In consideration of the payments to be made by Schering to ViroPharma hereunder, during the Option Period and (if Schering exercises the Option) the Negotiation
Period, except for licenses to Third Parties contracted to perform services, ViroPharma shall not directly or indirectly, without the prior written consent of Schering: 

  

	 	(i)	 	offer to license, sell, transfer or otherwise convey any rights to the Compound, Products, Patent Rights and Know-How in the Field, in the Territory to any Third Party, or

	

	 	(ii)	 	enter into discussions or negotiations with a Third Party for the purpose of discussing or evaluating a possible license, collaboration, joint venture, partnership or other business
relationship with regard to the development and/or commercialization of the Compound, Products, Patent Rights and Know-How in the Field, in the Territory. 

  

	 	(b)	 	Outside the Field. In consideration of the payments to be made by Schering to ViroPharma hereunder, during the Option Period and (if Schering exercises the Option) the
Negotiation Period, except for licenses to Third Parties contracted to perform services, ViroPharma shall not directly or indirectly, without the prior written consent of Schering, enter into discussions or negotiations with a Third Party involving
the exchange of proposed deal terms for a possible license, collaboration, joint venture, partnership or other business relationship with regard to the development and/or commercialization of the Compound, Products, Patent Rights and Know-How
outside the Field, in the Territory. 

  
 2.5       License Agreement. 
  

	 	(a)	 	If Schering exercises the Option, Schering and ViroPharma shall promptly enter into good faith negotiations to reach final agreement on the terms of the License Agreement. The
Parties shall use all commercially reasonable efforts to complete such negotiations and to enter into the License Agreement during the Negotiation Period. The License Agreement shall incorporate the basic license terms set forth in Exhibit A
(attached hereto), such other terms and conditions, consistent with those basic license terms, as are reasonable and customary in the pharmaceutical industry for agreements of this type, and such other terms as are necessary to enable ViroPharma to
fulfill its obligations under the SaSy Agreement. Notwithstanding the foregoing, the Parties acknowledge and agree that the terms and conditions of the License Agreement will not conflict with the terms and conditions of the SaSy Agreement and would
not obligate either Party to perform actions or omissions that would result in a breach of the SaSy Agreement. To the extent that the Parties reasonably determine that one or more of the provisions set forth in Exhibit A would conflict with the SaSy
Agreement or would obligate a Party to perform actions or omissions that would result in a breach of the SaSy Agreement, the Parties shall negotiate in good faith and shall amend such 

  
  

 5 

 provision(s) to the extent necessary to prevent such conflict or resultant breach while preserving to the
fullest extent possible the intent of the Parties as set forth in Exhibit A; provided, however, that no such modifications shall affect the scope of the licenses to be granted to Schering or increase Schering’s payment obligations
to ViroPharma, as set forth in Articles A-2 and A-6, respectively. 
  

	 	(b)	If the Parties are unable, after using good faith efforts, to reach agreement on all of the terms and conditions of the License Agreement during the Negotiation Period, then the
respective CEOs, or their designees, of Schering and ViroPharma shall have a period of fifteen (15) business days to meet and use good faith efforts to reach agreement on any unresolved terms and conditions of the License Agreement (the
“Unresolved Terms”). If such senior executives are unable to reach agreement on all of the Unresolved Terms during such period, then any remaining Unresolved Terms shall be resolved through binding arbitration pursuant to Article
11. 

  
 2.6    Schering’s Due Diligence. During the Option Period Schering shall conduct its due diligence review of available data and information related to the Compound and the Product to enable Schering to decide
whether or not to exercise the Option. ViroPharma shall make available to Schering, upon request, all such data and information as is reasonably necessary for such review, including without limitation the results of the Initial Studies and other
research and development activities to be provided to Schering under Sections 3.3 and 3.4. ViroPharma shall also arrange to provide Schering reasonable access to facilities, data and information related to the manufacture of the Compound and the
Product, and reasonable access to personnel of ViroPharma and/or its Third Party contractors involved with the development and/or manufacture of the Compound and Products. All access to personnel and facilities to be provided to Schering under this
Section 2.7 shall be during normal business hours and shall be subject to the confidentiality provisions of Article 5. 
  
 3.      DEVELOPMENT ACTIVITIES DURING THE OPTION PERIOD 
  
 3.1     Initial Studies. During the Option Period ViroPharma will use commercially reasonable
efforts to complete the Initial Studies, which shall be performed in accordance with the final approved Protocols. ViroPharma shall consult with Schering with respect to the design, implementation and conduct of each of the Initial Studies, and
shall provide Schering with copies of the Protocols proposed to be used for each of the Initial Studies. The final Protocol for each of the Initial Studies shall be subject to Schering’s written approval, and following such approval ViroPharma
shall not make any changes to the final Protocols for the Initial Studies without Schering’s prior written consent. 
  
 3.2     Cost of the Initial Studies. ViroPharma shall be solely responsible for any and all costs and expenses incurred in
connection with the Initial Studies, other than the CYP 3A Study Costs (as defined in Section 4.2). Schering’s sole financial obligation to ViroPharma under this Agreement shall be limited to payment of the Option fee and the CYP 3A Study Costs
in accordance with Article 4. 
  

 6 

 3.3     Study Results. Each Party shall designate a contact person to be
primarily responsible for communicating with such person’s counterpart on all issues concerning the Initial Studies. Through such contact person, ViroPharma shall keep Schering reasonably informed on and involved in the progress of the Initial
Studies, including by providing Schering with quarterly written status reports covering all of the Initial Studies. ViroPharma shall provide Schering with copies of all interim data and results generated from any of the Initial Studies, as well as
all of the final data and results of each of the Initial Studies, including access to or copies of the database from each Interim Study in a format mutually agreeable to the Parties, promptly after they become available. All such data and results
shall constitute Know-How, shall be treated as Confidential Information in accordance with Article 5, and shall only be used by Schering for the purpose of evaluating the Compound and the Product to determine whether or not to exercise the Option.
The Parties acknowledge that the data and results from the Initial Studies are subject to disclosure to and use by Sanofi-Synthelabo as set forth in Section 3.3 of the SaSy Agreement. 
  
 3.4     Other R&D Activities in the Field. During the Option Period (and if Schering
exercises the Option, during the Negotiation Period) ViroPharma shall not conduct any research and development activities related to the Compound and/or Products in the Field other than the Initial Studies, without Schering’s prior written
consent. In the event Schering does agree (in its sole discretion) to permit ViroPharma to perform any other activities related to the Compound and/or Products in the Field, ViroPharma shall obtain Schering’s prior written approval of relevant
research plans and/or protocols and shall keep Schering fully informed as to the planning, status and results of such additional activities. 
  
 3.5     Compassionate Use and Other R&D Activities Outside the Field. The Parties acknowledge that as of the Effective Date
ViroPharma is making the Compounds and/or Products available by request under its compassionate use programs for the ViroPharma Compassionate Use Indications and agree that ViroPharma shall have the right during the Option Period (and if Schering
exercises the Option, during the Negotiation Period) to continue such activities. ViroPharma shall also have the right to continue to perform retrospective analyses of data and results arising from its compassionate use programs for the ViroPharma
Compassionate Use Indications during the Option Period and the Negotiation Period. Except as permitted in this Section 3.5, during the Option Period (and if Schering exercises the Option, during the Negotiation Period) ViroPharma shall not undertake
any research or development activities for the Compound and/or the Products outside the Field without Schering’s prior written approval. 
  
 3.6     Compliance. ViroPharma shall be solely responsible for obtaining and maintaining any and all regulatory approvals
necessary for the performance of the Initial Studies, including, without limitation, any INDs, IRB approvals and patient informed consents. ViroPharma shall comply, and shall ensure that any of its contractors complies, with all applicable laws,
rules and regulations in connection with the performance of the Initial Studies, including without limitation, all pharmacovigilance responsibilities. Schering shall have no responsibility for any pharmacovigilance or other regulatory compliance
activities associated with the Initial Studies. 
  

 7 

 4.     PAYMENTS 
  
 4.1       Option Fee. 
  

	 	(a)	 	Amount. In consideration of the Option rights granted to Schering hereunder and the Initial Studies to be performed by ViroPharma during the Option Period, Schering shall pay
to ViroPharma a one time Option fee of three million dollars ($3,000,000) which payment shall be due within ******* days after the Effective Date. 

  

	 	(b)	 	Manner of Payment. The payment provided for in Section 4.1 shall be paid in U.S. dollars via wire transfer of immediately available funds for credit to the account of
ViroPharma, or as otherwise instructed in writing by ViroPharma. 

  
 4.2       CYP 3A Study Costs. 
  

	 	(a)	 	Amount. Schering shall pay ViroPharma all of ViroPharma’s out-of-pocket costs and expenses to the extent previously approved by Schering, but none of its internal costs
and expenses (including without limitation, any FTE costs), incurred in the performance of the study described in Section 1.6(d) (the “CYP 3A Study Costs”). 

	

	 	(b)	 	Manner of Payment. ViroPharma shall invoice Schering monthly for any CYP 3A Study Costs, which invoices shall be payable in U.S. dollars within ******* after the invoice date
by check, or as otherwise instructed by ViroPharma in writing. Notwithstanding the foregoing, if ViroPharma incurs any CYP 3A Study Costs in calendar year 2003, ViroPharma shall not invoice Schering for such costs until after January 1, 2004.

  
 4.3       Other
Costs. Except as expressly provided in this Agreement, including, without limitation, Section 4.2, each Party shall be solely responsible for its own internal and out-of-pocket costs and expenses incurred in connection with this Agreement.

  
 5.     CONFIDENTIALITY 
  
 5.1       Confidentiality. Each of
ViroPharma and Schering (in each case, as applicable, the “Receiving Party”) shall use only in accordance with this Agreement, and except as expressly permitted hereunder shall maintain in confidence and shall not disclose to any Third
Party, any Confidential Information received by it from, or on behalf of, the other Party (the “Disclosing Party”), without the prior written consent of the Disclosing Party. The foregoing obligations shall survive the expiration or
termination of this Agreement for a period of fifteen (15) years. These obligations shall not apply to Confidential Information that: 
  

 8 

	 	(a)	 	is known by the Receiving Party at the time of its receipt, and not through a prior disclosure by the Disclosing Party, as documented by the Receiving Party’s written records;

  

	 	(b)	 	is at the time of disclosure, or thereafter becomes, published or otherwise part of the public domain without breach of this Agreement by the Receiving Party;

	

	 	(c)	 	is obtained from a Third Party who has the legal right to make such disclosure and without any confidentiality obligation to the Disclosing Party; 

	

	 	(d)	 	is independently developed by the Receiving Party or its Affiliates without the aid, application or use of Confidential Information received from the Disclosing Party and such
independent development can be documented by the Receiving Party; or 

	

	 	(e)	 	is required by law, regulation, rule, act or order of any governmental authority or agency to be disclosed, provided that, 

  

	 	(i)	 	notice is promptly delivered to the Disclosing Party in order to provide it an opportunity to seek a protective order or other similar order with respect to such Confidential
Information, 

  

	 	(ii)	 	the Receiving Party discloses to the requesting entity only the minimum Confidential Information required to be disclosed in order to comply with the request, and

  

	 	(iii)	 	the Receiving Party only discloses the Confidential Information to the relevant governmental authority or agency, and otherwise continues to comply with the provisions of this
Section 5.1 with respect to the use and/or any other disclosures of such Confidential Information. 

  
 5.2       Publications. ViroPharma and Schering each acknowledges and agree that, during the Option Period (and if
Schering exercises the Option, the Negotiation Period), neither Party nor any of its Affiliates shall make any Public Presentation (as defined below) related to the Compound or the Products without the prior written consent of the other Party, which
consent may be withheld for any reason by the Party. For purposes of this Article 5, the term “Public Presentation” shall mean any manuscript, abstracts or other forms of public presentation, including, without limitation, slides and texts
of oral or other public presentations, and texts of any transmission through any electronic media, e.g. any computer access system such as the Internet, World Wide Web, etc. In the event either Party, its employees or consultants wish to make a
Public Presentation which relates to the Compound and/or the Products, including, without limitation, any publication of data and information generated in connection with the Initial Studies, as well as any pre-existing data or information related
to the Compound, the Party proposing such Public Presentation shall deliver to the other Party a copy of the proposed Public Presentation for review at least sixty (60) days prior to its submission. The reviewing Party shall have the right: to
propose modifications to the Public Presentation; to prohibit the Public 
  

 9 

 Presentation for patent reasons, trade secret reasons or business reasons; or to request a reasonable delay in
publication or presentation in order to protect patentable information. If the reviewing Party requests a delay, the publishing Party shall delay submission or presentation for a period of up to ninety (90) days to enable patent applications
protecting each Party’s rights in such information to be filed. If the reviewing Party requests modifications to the Public Presentation, the publishing Party shall edit such Public Presentation to prevent disclosure of the reviewing
Party’s Confidential Information prior to its submission. If the reviewing Party prohibits publication, the publishing Party shall not publish the Public Presentation. Notwithstanding the foregoing, this Section 5.2 shall not apply to the
extent that any disclosures or submissions are required to be made pursuant to applicable laws or regulations, including, without limitation, SEC rules and regulations, or any applicable NASDAQ rules or regulations; provided that ViroPharma
shall provide Schering with advance written notice of such disclosure or submission so that Schering can review and comment on the proposed disclosure or submission, and shall seek confidential treatment of the proposed disclosure or submission to
the extent available. 
  
 5.3      
Publicity. Each Party (on behalf of itself and its Affiliates) acknowledges and agrees that it may not: (i) use the name of the other Party, or such Party’s Affiliates, in any publicity or advertising; or (ii) issue a press release or
otherwise publicize or disclose to any Third Party, other than as ViroPharma is required to do so by the SaSy Agreement, any information related to the existence of this Agreement, any activities under this Agreement, or the terms or conditions of
this Agreement or the License Agreement, without the prior written consent of the other Party (which consent may be withheld in such Party’s sole discretion). Notwithstanding the foregoing, this Section 5.3 shall not apply to the extent that
any disclosures or submissions are required to be made pursuant to applicable laws or regulations, including, without limitation, SEC rules and regulations, or any applicable NASDAQ rules or regulations; provided that ViroPharma shall provide
Schering with advance written notice of such disclosure or submission so that Schering can review and comment on the proposed disclosure or submission, and shall seek confidential treatment of the proposed disclosure or submission to the extent
available. 
  
 5.4       Filing
of Agreement. To the extent that ViroPharma reasonably determined that it is required to file this Agreement with the SEC such filing with and disclosure by the SEC shall not constitute a breach of this Agreement; provided that ViroPharma
provides Schering with advance written notice of filing so that Schering can review and comment on the proposed filing, and seeks confidential treatment of the filed Agreement to the extent available. 
  
 6.     INTELLECTUAL PROPERTY 
  
 6.1       Excluded Intellectual
Property. Except for the Option granted by ViroPharma to Schering pursuant to Section 2.1 of this Agreement, under no circumstances shall a Party hereto, as a result of this Agreement, obtain any ownership interest in, or any other right or
license to, any existing or future technology, know-how, patents, patent applications or products of the other Party. 
  

 10 

 6.2       Responsibility for Patent Rights. During the Option
Period, ViroPharma shall remain primarily responsible, at its expense, for the preparation, filing, prosecution, maintenance, enforcement and defense of the Patent Rights in the Territory. During the Option Period, ViroPharma shall keep Schering
reasonably informed as to the status of the Patent Rights. 
  
 7.     REPRESENTATIONS AND WARRANTIES 
  
 7.1       Representations and Warranties of Each Party. As of the Effective Date, each of ViroPharma and Schering hereby represents, warrants and covenants to the other Party as
follows: 
  

	 	(a)	 	it has the power and authority to execute and deliver this Agreement and to perform its obligations hereunder; 

  

	 	(b)	 	the execution, delivery and performance by such Party of this Agreement and its compliance with the terms and provisions hereof does not conflict with or result in a breach of any
of the terms and provisions of, or constitute a default under, (i) a loan agreement, guaranty, financing agreement, agreement affecting a product, or other agreement or instrument binding or affecting it or its property; (ii) the provisions of its
charter documents or bylaws (as applicable); or (iii) any order, writ, injunction or decree of any court or governmental authority entered against it or by which any of its property is bound; 

  

	 	(c)	 	the execution, delivery and performance of this Agreement by such Party does not require the consent, approval, or authorization of, or notice, declaration, filing or registration
with, any governmental or regulatory authority, and the execution, delivery or performance of this Agreement will not violate any law, rule or regulation applicable to such Party; 

  

	 	(d)	 	this Agreement has been duly authorized, executed and delivered and constitutes such Party’s legal, valid and binding obligation enforceable against it in accordance with its
terms subject, as to enforcement, to bankruptcy, insolvency, reorganization and other laws of general applicability relating to or affecting creditors’ rights and to the availability of particular remedies under general equity principles; and

  

	 	(e)	 	it shall comply with all applicable material laws and regulations relating to its activities under this Agreement. 

  
 7.2       ViroPharma’s
Representations. As of the Effective Date, ViroPharma hereby represents and warrants to Schering as follows: 
  

 11 

	 	(a)	 	to the best of ViroPharma’s knowledge, the existing Patent Rights in the Field in the Territory are subsisting and are not invalid or unenforceable, in whole or in part;

  

	 	(b)	 	it has the full right, power and authority to grant all of the right, title and interest in the Option granted under Article 2; 

  

	 	(c)	 	it has not previously assigned, transferred, conveyed or otherwise encumbered its right, title and interest in the Compound, Products, Patent Rights or Know-How in the Field in the
Territory, except pursuant to the Copromotion and Codevelopment Agreement by and between ViroPharma Incorporated and Aventis Pharmaceuticals, Inc., dated September 9, 2001, as subsequently terminated by the Settlement Agreement and Release by and
among ViroPharma Incorporated, VCO Incorporated and Aventis Pharmaceuticals, Inc, dated August 1, 2002; 

  

	 	(d)	 	except for (i) the purported class action litigation described in ViroPharma’s Form 10-Q filed with the United States Securities and Exchange Commission for the period ending
June 30, 2003, and (ii) the case Purdue Research Foundation v. Sanofi-Synthelabo, S.A., No. 03CV01924 (D.D.C. filed Sept. 16, 2003), there are no filed claims, judgments or settlements against or owed by ViroPharma, and to the best of
ViroPharma’s knowledge, there are no pending or threatened claims or litigation relating to the Compound, Patent Rights or Know-How; 

  

	 	(e)	 	it is the sole and exclusive owner and/or licensee of the existing Patent Rights and Know-How in the Field in the Territory, all of which are free and clear of any liens, charges
and encumbrances; 

  

	 	(f)	 	to the best of ViroPharma’s knowledge, the Patent Rights and Know-How and the development, manufacture, import, export, offer to sell, use and sale of Products in the Field in
the Territory do not interfere or infringe on any intellectual property rights owned or possessed by any Third Party; and 

  
 as of the Effective Date, ViroPharma hereby covenants to Schering as follows: 
  

	 	(g)	 	prior to the effective date of the License Agreement it will disclose to Schering all Know-How in ViroPharma’s possession or control which is reasonably requested by Schering
and directly related to the development, manufacture, marketing or sale of the Product in the Field in the Territory; 

  

	 	(h)	 	it will use diligent efforts not to diminish the right under the Patent Rights and Know-How granted to Schering hereunder,
including            , without limitation, by not committing or permitting any acts or omissions which would cause the breach of SaSy Agreement, or any other agreements between itself and
any Third Party, which provide for intellectual property rights applicable to the development, manufacture, use or sale of Products in the Field in the Territory, and in 

  

 12 

 connection therewith, ViroPharma agrees to provide Schering promptly with notice of any such alleged
breach and ViroPharma is in compliance in all material respects with any such agreements; and 
  

	 	(i)	 	(i)     it will not amend the SaSy Agreement in any way that will reduce the scope of Schering’s right or potential right existing as of the date of the
Option Agreement to make, have made, use, import, export, offer for sale or sell Compound or Product in the Field in the Territory, or otherwise adversely affect the rights granted to Schering under this Agreement without Schering’s prior
written consent. 

  
 7.3       Schering’s Representations. As of the Effective Date, Schering hereby represents, warrants and covenants to ViroPharma as follows: 
  

	 	(a)	 	it is a corporation duly organized and validly existing under the laws of the state or other jurisdiction of its incorporation or formation; and 

  

	 	(b)	 	the execution, delivery and performance of this Agreement by Schering has been duly authorized by all requisite corporate action. 

  
 7.4       Continuing Representations.
The representations and warranties of each Party contained in Sections 7.1, 7.2 and 7.3 shall be made as of the Effective Date. The breach as of the Effective Date of a representation or warranty contained in Section 7.1, 7.2 or 7.3, shall not
become unenforceable after the Effective Date solely by the passage of time. 
  
 7.5       No Inconsistent Agreements. As of the Effective Date neither Party has in effect, and after the Effective Date neither Party shall enter into, any oral or written
agreement or arrangement that would be inconsistent with its obligations under this Agreement. 
  
 7.6       Validity and Scope. Nothing in this Agreement shall be construed as a warranty or representation by either Party as to the validity or scope of any Patent Right.

  
 7.7       Disclaimer. THE
WARRANTIES OF EACH PARTY IN THIS ARTICLE 7 ARE IN LIEU OF ANY OTHER WARRANTIES, EXPRESS OR IMPLIED, INCLUDING, WITHOUT LIMITATION, ANY IMPLIED WARRANTIES OF NONINFRINGEMENT, ANY IMPLIED WARRANTIES OF MERCHANTABILITY OR ANY IMPLIED WARRANTIES OF
FITNESS FOR A PARTICULAR PURPOSE ALL OF WHICH ARE HEREBY SPECIFICALLY EXCLUDED AND DISCLAIMED. 
  
 8.     INDEMNIFICATION 
  
 8.1       Indemnification by Schering. Except to the extent caused by ViroPharma’s negligence or willful misconduct and subject to the limitations in Section 8.5, Schering
shall indemnify, defend and hold harmless ViroPharma, its Affiliates, and each of their employees, officers, directors and agents (each, a “ViroPharma Indemnified Party”) from and against any 
  

 13 

 and all liability, loss, damage, cost, and expense (including reasonable attorneys’ fees) which the ViroPharma
Indemnified Party may incur, suffer or be required to pay resulting from or arising in connection with, (a) the breach by Schering of any covenant, representation or warranty contained in this Agreement, or (b) any negligent act or omission, or
willful misconduct of Schering during the term of this Option Agreement. 
  
 8.2       Indemnification by ViroPharma. Except to the extent caused by Schering’s negligence or willful misconduct and subject to the limitations in Section 8.5, ViroPharma
shall indemnify, defend and hold harmless Schering, its Affiliates, and each of their employees, officers, directors and agents (each, a “Schering Indemnified Party”) from and against any and all liability, loss, damage, cost, and expense
(including reasonable attorneys’ fees) which the Schering Indemnified Party may incur, suffer or be required to pay resulting from or arising in connection with, (a) the breach by ViroPharma of any covenant, representation or warranty contained
in this Agreement, (b) any negligent act or omission, or willful misconduct of ViroPharma during the term of this Option Agreement, or (c) the performance of the Initial Studies or any other research and development activities during the term of
this Option Agreement related to the Compound and/or Products in the Field by or on behalf of ViroPharma. 
  
 8.3       Conditions to indemnification. The obligations of the indemnifying Party under Sections 8.1 and 8.2 are
conditioned upon the delivery of written notice to the indemnifying Party of any potential liability or claim for which the indemnified Party will seek indemnification promptly after the indemnified Party becomes aware of such potential liability or
claim; provided that failure to provide such notice shall not constitute a waiver of, or result in the loss of, such Party’s right to indemnification under Section 8.1 or 8.2, as appropriate, except to the extent that the indemnifying
Party’s rights, and/or its ability to defend against such liability or claim, are materially prejudiced by such failure to notify. The indemnified Party, its employees and agents shall cooperate fully with the indemnifying Party and its legal
representatives in the investigation of any action, claim or liability covered by this indemnification. The indemnifying Party shall have the right to assume the defense of any suit or claim related to the liability if it has assumed responsibility
for the suit or claim in writing. Notwithstanding the foregoing, if in the reasonable judgment of the indemnified Party, such suit or claim involves an issue or matter which could have a materially adverse effect on the business operations or assets
of the indemnified Party, the indemnified Party may waive its rights to indemnity under this Agreement and control the defense or settlement thereof, but in no event shall any such waiver be construed as a waiver of any indemnification rights such
Party may have at law or in equity. If the indemnifying Party defends the suit or claim, the indemnified Party may participate in (but not control) the defense thereof at its sole cost and expense. 
  
 8.4       Settlements. Neither Party may
settle a claim or action related to a liability or claim which is subject to indemnification hereunder without the consent of the other Party, if such settlement would impose any monetary obligation on the other Party or require the other Party to
submit to an injunction or otherwise limit the other Party’s rights under this Agreement, which consent shall not be unreasonably withheld. Any payment made by a Party to settle any such claim or action shall be at its own cost and expense.

  

 14 

 8.5       Limitation of Liability. With respect to any claim by one
Party against the other arising out of the performance or failure of performance of the other Party under this Agreement, the Parties expressly agree that the liability of such Party to the other Party for such breach shall be limited under this
Agreement or otherwise at law or equity to direct damages only and in no event shall a Party be liable for any punitive, exemplary or consequential damages, including lost profits. 
  
 9.     TERM/TERMINATION 
  

9.1       Term and Expiration. The term of this Agreement shall commence on the Effective Date and, unless
terminated earlier pursuant to Section 9.2 or 9.3, shall continue in full force and effect as follows: 
  

	 	(a)	 	if Schering does not exercise the Option, this Agreement shall expire upon expiration or termination of the Option Period; or 

  

	 	(b)	 	if Schering does exercise the Option, this Agreement shall expire upon the earlier of (i) expiration of the Negotiation Period, including as it may be extended, or (ii) the
effective date of the License Agreement. 

  
 9.2       Termination by Schering. Notwithstanding anything contained herein to the contrary, Schering shall have the unilateral right to terminate this Agreement, with or without cause, at any time by
giving thirty (30) days advance written notice to ViroPharma. 
  
 9.3       Termination for Cause. This Agreement may be terminated by written notice by a Party at any time during the term of this Agreement as follows: 
  

	 	(a)	 	Termination for Breach. If the other Party is in breach of its material obligations hereunder by causes and reasons within its control and has not cured such breach within
sixty (60) calendar days, (fifteen (15) business days in the case of a monetary breach) after written notice of the breach; or 

  

	 	(b)	 	Termination for Insolvency. Upon the filing or institution of bankruptcy, reorganization, liquidation or receivership proceedings, or upon an assignment of a substantial
portion of the assets for the benefit of creditors by the other Party or in the event a receiver or custodian is appointed for such Party’s business, or if a substantial portion of such Party’s business is subject to attachment or similar
process; provided, however, in the case of any involuntary bankruptcy proceeding such right to terminate shall only become effective if such proceeding is not dismissed within sixty (60) days after the filing thereof. The Parties acknowledge and
agree that the Option is and shall otherwise be deemed to be, for purposes of Section 365(n) of the Bankruptcy Code, a licenses of rights to “intellectual property” as defined under Section 101(52) of the Bankruptcy Code, and that Schering
shall retain and may fully exercise all of its rights and elections under the Bankruptcy Code. 

  

 15 

 9.4       Effect of Termination. In the event that this Agreement
expires or is terminated, then all rights granted to Schering hereunder shall terminate and revert to ViroPharma. In addition to the foregoing, in the event that Schering terminates this Agreement pursuant to Section 9.3(a) because of a breach by
ViroPharma, ViroPharma shall return the Option Fee described in Section 4.1 within thirty (30) days of such termination, and such return of the Option Fee and such termination shall be Schering’s sole and exclusive remedy for such breach.

  
 9.5       Accrued
Rights/Surviving Terms. Expiration or termination of this Agreement shall not release either Party from any obligation accruing prior to or upon such expiration or termination. In addition, the following provisions shall survive expiration or
termination of this Agreement: Sections 4.2, 6.1, 9.4 and 9.5, and Articles 5, 7, 8, 10 and 12; provided that such provisions shall not survive in the event that the Parties execute and enter into the License Agreement. 
  
 10.    ASSIGNABILITY 
  
 This Agreement may not be assigned or otherwise transferred by either Party
without the prior written consent of the other Party. The foregoing notwithstanding, either Party may, without the other Party’s consent, assign its rights and obligations under this Agreement, (a) to any Affiliate, or (b) in connection with a
merger, consolidation or sale of substantially all of its assets pertaining to this Agreement to an unrelated Third Party, provided, however, that the assigning Party’s rights and obligations under this Agreement shall be assumed
by its successor in interest in any such transaction and shall not be transferred separate from all or substantially all of its other business assets relating to the subject matter hereof, including those business assets that are the subject of this
Agreement. Any purported assignment in violation of this Section 10.1 shall be void. Any permitted assignee shall assume all obligations of its assignor under this Agreement. 
  
 11.    ARBITRATION OF LICENSE TERMS 
  
 11.1       Selection of License Term Panel. Within ten (10) business days of the
expiration of the fifteen (15) day period provided for in Section 2.5(b) of this Option Agreement, each Party shall appoint an independent expert, knowledgeable about pharmaceutical licensing terms, to serve on the License Agreement arbitration
panel (the “License Term Panel”). The two independent experts so appointed by the Parties, shall, within ten (10) business days thereafter, appoint a neutral, similarly knowledgeable third independent expert. Such neutral third independent
expert shall serve as the chairperson of the License Term Panel. Each of the members of the License Term Panel shall be required to sign a secrecy agreement, acceptable in form to both Parties, with respect to any information provided by either
Party during the arbitration procedure. 
  
 11.2       Written Submissions. Within five (5) business days after the chairperson of the License Term Panel is appointed, each Party shall submit to each member of the License Term 
  

 16 

 Panel, and to the other Party, a written statement setting forth the relevant facts with respect to the Unresolved Terms,
a single, complete proposed resolution of the Unresolved Terms (the “Proposal”) and arguments supporting such Party’s Proposal. The Proposal shall be limited to the Unresolved Terms and terms potentially inconsistent with or resulting
in a breach of the SaSy Agreement only and shall not alter any of the other terms and conditions of the License Agreement (including, without limitation, those set forth in Exhibit A) except as such terms may be inconsistent with or resulting in a
breach of the SaSy Agreement. 
  
 11.3       Oral Arguments. Within five (5) business days after such written statements are provided to the License Term Panel, the License Term Panel and appropriate representatives of each Party shall
meet so that the Parties can present oral arguments to the License Term Panel, and the License Term Panel can have the opportunity to ask questions of the Parties. The location of such meeting shall be in New York, New York. Each Party shall have
two (2) hours to present its arguments to the License Term Panel and thirty (30) additional minutes to rebut the arguments made by the other Party. The License Term Panel shall designate which Party shall first present its oral argument to the
License Term Panel. 
  
 11.4      
Arbitration Panel Decision. Within five (5) business days after such meeting, the License Term Panel shall render a decision on the Dispute, which decision shall be reduced to writing by the chairperson of the License Term Panel and signed by
each member of the License Term Panel, and which decision shall ensure that the License Agreement resulting from such decisions would not be inconsistent with and would not obligate a Party to perform actions or omissions that would result in a
breach of the SaSy Agreement. The chairperson of the License Term Panel shall be responsible for immediately providing a copy of the written decision to each Party. Such decision shall be binding with respect to any Unresolved Terms under this
Option Agreement. 
  
 11.5      
Costs. Each Party shall be responsible for its own costs (including, without limitation, reasonable attorneys fees) and expenses incurred in such arbitration procedures and the cost of the License Term Panel shall be shared equally by the
Parties; provided, however, that if the License Term Panel determines that the action of any Party was arbitrary, frivolous or in bad faith, the License Term Panel may award such costs and expenses to the prevailing Party. 
  
 11.6       Confidentiality. The
arbitration proceeding shall be confidential and, except as required by law, neither Party shall make (or instruct the License Term Panel to make) any public announcement with respect to the proceedings or decision of the License Term Panel without
the prior written consent of the other Party. The existence of any dispute submitted to arbitration, and the award of the License Term Panel, shall be kept in confidence by the Parties and the License Term Panel, except as required in connection
with the enforcement of such award or as otherwise required by applicable law. Notwithstanding the foregoing, ViroPharma shall be permitted to file the final terms of the License Agreement with the SEC, and such filing and disclosure shall not be
considered a breach of this Option agreement or of the License Agreement. 
  

 17 

 11.7       Jurisdiction. For the purposes of these arbitration
provisions, the Parties acknowledge their diversity and agree to accept the jurisdiction of the Federal District Courts in New York, New York for the purposes of enforcing the result of arbitration under this Article 11. 
  
 11.8       Application. The procedures
specified herein shall be the sole and exclusive procedures for the resolution of Unresolved Terms. 
  
 12.    MISCELLANEOUS 
  
 12.1       Independent Contractors. It is expressly agreed that ViroPharma and Schering are independent contractors and that the relationship between the two Parties shall not
constitute a partnership, joint venture or agency. Neither ViroPharma nor Schering shall have the authority to make any statements, representations or commitments of any kind, or to take any action, which shall be binding on the other, without the
prior consent of the other Party to do so. 
  
 12.2       Notices. Any notices, invoices and communications hereunder shall be deemed made (a) five (5) business days after having been sent by registered or certified mail, postage prepaid, (b) one (1)
business day after having been sent by overnight mail, with signed, confirmed receipt, (c) on the day of hand delivery, or (d) on the day of facsimile transmission, upon confirmation of receipt, if addressed to the Party to receive such notice,
invoice or communication at the addresses given below, or such other address as may hereafter be designated by notice in writing. 
  
 If to ViroPharma: 
  
   ViroPharma Incorporated 
   405 Eagleview Boulevard 
   Exton, Pennsylvania 19341 
   Attention: General Counsel 
   Fax – 610-458-7380 
  
 If to Schering: 
  
   Schering
Corporation 
   2000 Galloping Hill Road 
   Kenilworth, New Jersey 07032 
   Attention: Vice President, Business Development 
   Fax—(908)
298-7366 
  
   cc: Law Department –
Senior Legal Director, Licensing 
   Fax—(908) 298-2739 
  
 12.3       Entire Agreement. This
Agreement, together with the exhibits hereto, contains the entire understanding of the Parties with respect to the subject matter hereof. All previous agreements are superseded hereby and all express or implied agreements and understandings, either
oral or written, heretofore made are expressly merged in and made a part of this 
  

 18 

 Agreement. This Agreement may be amended, or any term hereof modified, only by a written instrument duly executed by
authorized representatives of both Parties hereto. 
  
 12.4      Dispute Resolution. This Section 12.4 shall not apply to disputes otherwise subject to Section 2.5(a). 
  

	 	(a)	 	Cooperation. In the event that a dispute or disagreement arises between the Parties with respect to an issue relating to this Agreement or the Parties’ performance
hereunder, then upon written notice to the other Party, authorized representatives of Schering and ViroPharma shall promptly meet and use good faith efforts to reach agreement on resolution of the issue (the “Dispute”). In the event the
that such representatives of Schering and ViroPharma are unable to reach agreement on the Dispute in such meeting, then either Party shall have the right to submit the Dispute to binding arbitration in accordance with the provisions of Section
12.4(b) by providing written notice to the other Party within two (2) weeks after such meeting. 

  

	 	(b)	 	Arbitration. All Disputes arising in connection with this Agreement which cannot be resolved by the Parties shall be finally settled under the Commercial Arbitration Rules of
the American Arbitration Association then in effect, as modified by the provisions set forth in Exhibit B. 

  
 12.5      Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State
of New York without giving effect to the choice of laws provisions thereof. 
  
 12.6      Descriptive Headings. The captions to the several Articles and Sections hereof are not a part of this Agreement, and are merely guides or labels to assist in locating and
reading the several Articles and Sections hereof. 
  
 12.7      Counterparts. This Agreement shall become binding when any one or more counterparts hereof, individually or taken together, shall bear the signatures (including by facsimile) of each of the
Parties hereto. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. 
  
 12.8      Force Majeure. Failure of any
Party to perform its obligations under this Agreement (except the obligation to make payments when properly due) shall not subject such Party to any liability or place them in breach of any term or condition of this Agreement if such failure is
caused by any cause beyond the reasonable control of such non-performing Party, including without limitation, acts of God, fire, explosion, flood, drought, war, riot, terrorism, sabotage, embargo, strikes or other labor trouble, failure in whole or
in part of suppliers to deliver on schedule materials, equipment or machinery, interruption of or delay in transportation, a national health emergency or compliance with any order or regulation of any government entity acting with color of right,
provided, however, that the Party affected shall promptly notify the other Party of the condition constituting force majeure as defined herein and shall exert 
  

 19 

 reasonable efforts to eliminate, cure and overcome any such causes and to resume performance of its obligations with all
possible speed. If a condition constituting force majeure as defined herein exists for more than thirty (30) consecutive days, the Parties shall meet to negotiate a mutually satisfactory solution to the problem, if practicable. 
  
 12.9      Severability. If any provision
of this Agreement is declared illegal, invalid or unenforceable by a court having competent jurisdiction, it is mutually agreed that this Agreement shall endure except for the part declared invalid or unenforceable by order of such court,
provided, however, that in the event that the terms and conditions of this Agreement are materially altered, the Parties shall, in good faith, renegotiate the terms and conditions of this Agreement to reasonably substitute such invalid
or unenforceable provision in light of the intent of this Agreement. 
  
 12.10      Export Control. This Agreement is made subject to any restrictions concerning the export of products or technical information from the United States of America which may be imposed upon or
related to ViroPharma or Schering from time to time by the government of the United States of America. Furthermore, Schering agrees that it will not export, directly or indirectly, any technical information acquired from ViroPharma under this
Agreement or any products using such technical information to any country for which the United States government or any agency thereof at the time of export requires an export license or other governmental approval, without first obtaining the
written consent to do so from the Department of Commerce or other agency of the United States government when required by an applicable statute or regulation. 
  

12.11      Further Actions. Each Party agrees to execute, acknowledge and deliver such further instruments, and to
do all such other acts, as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement. 
  
 IN WITNESS WHEREOF, the Parties have caused their duly authorized officers to execute and deliver this Agreement as of the last date set forth below.

  
  
  

																			
	 SCHERING CORPORATION
	 	 	 	 	 	 	 	 	 	 	 	 	 	VIROPHARMA INCORPORATED
										
	 By:
	 	/S/     MICHAEL J. DUBOIS	 	 	 	 	 	 	 	 	 	 	 	 	 	By:	 	/S/     MICHEL DE ROSEN
	 	 	
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	

	 Name:
	 	Michael J. DuBois	 	 	 	 	 	 	 	 	 	 	 	 	 	Name:	 	Michel de Rosen
	 	 	
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	

	 Title:
	 	Senior Vice President	 	 	 	 	 	 	 	 	 	 	 	 	 	Title:	 	President & CEO
	 	 	
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	

	 Date:
	 	November 25, 2003	 	 	 	 	 	 	 	 	 	 	 	 	 	Date:	 	November 25, 2003
	 	 	
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	

  
  

 20 

 EXHIBIT A 
  

 
 Basic Terms of License Agreement 
  
 The Parties have agreed that the following terms and conditions shall be included in and form
the basis for the License Agreement. However, the terms and conditions set forth in this Exhibit A will not become effective unless and until Schering has exercised the Option and the Parties have executed the License Agreement. 
  
 A-1   Definitions. Capitalized terms used in the License Agreement, whether
used in the singular or plural, shall have the respective meanings set forth in the Option Agreement or in this Article A-1. 
  
 A-1.1   “FDA” shall mean the United States Food and Drug Administration or any successor agency thereto. 
  
 A-1.2   “First Commercial Sale” shall mean, with respect
to the Product in a given country in the Territory, the first sale by Schering or its Affiliates to any Third Party (which is not an Affiliate or sublicensee) of such Product following regulatory approval to market and sell such Product in such
country for an indication in the Field. 
  
 A-1.3
  “License Effective Date” shall mean the effective date of the License Agreement incorporating the terms set forth in this Exhibit A. 
  
 A-1.4   “Net Sales” shall mean the invoiced sales of Products in the Territory by Schering and its Affiliates to unaffiliated Third
Parties (exclusive of intercompany transfers or inter-company sales), after deducting: 
  

	 	(a)	 	customary trade discounts, reasonable quantity and cash discounts, and/or rebates (including without limitation, chargebacks, trade rebates, managed care rebates, government rebates
and other reasonable and customary discounts, allowances, credits and rebates); 

  

	 	(b)	 	allowances or credits to customers on account of rejection or return of Products or on account of retroactive price reductions affecting Products; 

  

	 	(c)	 	freight and insurance; and 

  

	 	(d)	 	value added, sales, use or turnover taxes, and excise taxes or customs duties or local charges or taxes, included in the invoiced amount. 

  
 A-1.5   “Schering Subsidiary” shall mean an Affiliate of
Schering that is directly or indirectly one hundred percent (100%) owned or controlled by Schering-Plough Corporation (the corporate parent of Schering). 
  

 i 

 A-1.6   “Trademarks” shall mean any and all trademarks in the Territory for use in
connection with the marketing and sale of the Products in the Field which are owned or controlled by ViroPharma, including, without limitation, any such trademarks licensed to ViroPharma under the SaSy Agreement. 
  
 A-1.7   “Valid Claim” shall mean a composition of matter
claim, or method of use claim (or its equivalent) of an issued and unexpired patent in a country in the Territory which covers the Compound, is included within the Patent Rights, that provides market exclusivity (as defined below) as to the Product,
that absent the license provided hereunder would be infringed by Schering’s marketing, distribution or sale of Compound or Product in such country of the Territory, and which (i) has not been revoked or held unenforceable or invalid by a
decision of a court or other governmental agency of competent jurisdiction, unappealable or unappealed within the time allowed for appeal; or (ii) has not been abandoned, disclaimed, or admitted to be invalid or unenforceable through reissue or
disclaimer or otherwise. Market exclusivity means that sales of all Product by Schering or its Affiliates in a country in the Territory (“Schering Sales”) constitute more than 75% by volume of the sum of Schering Sales and all sales of
Product by entities other than Schering or its Affiliates in such country. 
  
 A-2.  LICENSE 
  
 A-2.1  
License Grant. ViroPharma hereby grants to Schering and/or its designated Affiliate(s) an exclusive (even as to ViroPharma) license under the Patent Rights and Know-How (including, without limitation, the Patent Rights and Know-How licensed
to ViroPharma under the SaSy Agreement) in the Field in the Territory to make, have made, use, import and export, offer for sale and sell the Compound and the Products. In the case of Patent Rights and Know-How licensed to ViroPharma pursuant to the
SaSy Agreement, the license to Schering shall be limited at any time during the term of this Agreement to only those rights received by ViroPharma under the SaSy Agreement (including as it may be amended), as such rights exist at such time. Upon
designating any of its Affiliates that is not also a Schering Subsidiary to receive a license under this Section A-2.1, Schering shall notify ViroPharma in writing of such designation, and ViroPharma shall have the right to provide such information
to Sanofi-Synthelabo. For the sake of clarity, in the case of Patent Rights and Know-How licensed to ViroPharma pursuant to the SaSy Agreement, the sublicense to Schering shall be to the full extent of the rights licensed to ViroPharma, and
ViroPharma shall not reduce such extent by its acts or omissions without the prior written consent of Schering. 
  
 A-2.2   Trademark License. ViroPharma hereby grants to Schering and/or its designated Affiliate(s) an exclusive (even as to ViroPharma)
license under the Trademarks in the Territory to make, have made, use, import and export, offer for sale and sell the Products in the Field. The license granted under this Section A-2.2 includes an exclusive sub-license to all of the corresponding
rights and licenses granted to ViroPharma in the Field in the Territory under the SaSy Agreement with respect to the Products, but is limited at any time during the term of this Agreement to only those rights received by ViroPharma under the SaSy
Agreement (including as it may be amended), as such rights exist at such time. Upon designating any of its Affiliates to receive a license under this Section A-2.2, Schering shall notify Sanofi-Synthelabo in writing of 
  

 ii 

 such designation. For the sake of clarity, in the case of Trademarks licensed to ViroPharma pursuant to the SaSy
Agreement, the sublicense to Schering shall be to the full extent of the rights licensed to ViroPharma, and ViroPharma shall not reduce such extent by its acts or omissions without the prior written consent of Schering. 
  
 A-2.3   Sublicenses. The licenses granted to Schering under
Sections A-2.1 and A-2.2 shall include the limited right to grant sublicenses to Third Parties contracted by Schering or its Affiliates to perform services in connection with the development and/or commercialization of the Products in the Field in
the Territory, but in the case of Patent Rights and Know-How licensed to ViroPharma pursuant to the SaSy Agreement, and sublicensed to Schering under Section A-2.1 or A-2.2, Schering’s right to sublicense shall be limited at any time during the
term of this Agreement to only those rights received by ViroPharma under the SaSy Agreement (including as it may be amended), as such rights exist at such time, and shall be subject to the prior consent of Sanofi-Synthelabo. Any such sublicenses
shall be granted solely for the purpose of, and only to the extent necessary to, enable such contractors to perform the relevant services for Schering, shall be consistent with the terms and conditions of the License Agreement and the SaSy
Agreement, and shall not include any right to grant further sublicenses. Except as expressly provided for in this Section A-2.3, Schering shall have no right to grant sublicenses under this License Agreement. Nothing in this Agreement shall prevent
Schering from contracting with Third Parties to assist in the development or commercialization of Compound and Products in the Territory in the Field to the extent that the activities of such Third Parties do not require a sublicense under Patent
Right, Know-How or Trademarks. For the sake of clarity, in the case of Patent Rights and Know-How licensed to ViroPharma pursuant to the SaSy Agreement, the sublicense to Schering shall be to the full extent of the rights licensed to ViroPharma, and
ViroPharma shall not reduce such extent by its acts or omissions without the prior written consent of Schering. 
  
 A-2.4   Rights Outside the Field. 
  
 ViroPharma shall not develop or commercialize, or grant or convey to any third party any rights to develop or commercialize, the Compound and/or Products
for use outside the Field without the prior written consent of Schering. Any such written consent granted by Schering shall include the terms under which such development or commercialization may proceed. 
  

	 	(a)	 	Evaluation of LTI. During the ******* period immediately after the License Effective Date (the “Evaluation Period”) the Parties shall meet to discuss whether or not
ViroPharma should be permitted to proceed with the development and commercialization of the Compound and Products in the Territory for the prevention or treatment of certain life-threatening disease or conditions caused by picornaviruses, which may
include, without limitation, the ViroPharma Compassionate Use Indications (the “Life Threatening Indications” or “LTI”). Such discussions shall include, without limitation, consulting with the FDA and/or other regulatory
authorities in the Territory to assess the risk that such development and/or commercialization activities would be relevant to and/or could raise issues with respect to, or otherwise adversely affect, the Compound and/or 

  

 iii 

 Products being developed and commercialized by Schering in the Field under the License Agreement. On or
before the expiration of the Evaluation Period, Schering shall determine, based upon the discussions and risk assessment conducted by the Parties, whether or not the continued development and subsequent commercialization of the Compound and/or
Products for LTI presents an unacceptable risk to the development and/or commercialization of the Compound and/or Products in the Field. Schering shall notify ViroPharma in writing of such determination on or before the expiration of the Evaluation
Period. 
  

	 	(b)	 	Decision on LTI. If Schering notifies ViroPharma that the risk to the Compound and/or the Products in the Field is unacceptable, then effective on the date of such notice to
ViroPharma (the “Notice Date”), the Field shall be expanded to mean (i) any and all indications involving the treatment or prevention of picornavirus infections (including, without limitation, the common cold and LTI), and (ii) any Other
Indications (as defined in the SaSy Agreement) to which ViroPharma obtains rights pursuant to the SaSy Agreement (the “Expanded Field”), and all references in the License Agreement to the “Field” shall thereafter mean the
Expanded Field; provided that Schering’s rights shall be subject to Section 2.4(c). In such event, on or immediately after the Notice Date, ViroPharma shall discontinue all efforts to develop and/or commercialize the Compound and/or Products in
the Expanded Field and terminate any discussions or interactions with third parties with regard to possible licenses or other business transactions related thereto; provided, however, that ViroPharma’s compassionate use programs for the
Compound and/or Products shall be governed by and subject to Section A-3.3. 

  

	 	(c)	 	Restriction on Schering Activity. If the Field is expanded pursuant to Section 2.4(b), Schering covenants to ViroPharma that notwithstanding anything in the License Agreement
to the contrary it shall not at any time during the term of the License Agreement undertake any actions to develop or commercialize, or to license any third party to develop or commercialize, the Compound and/or the Products in the Territory for any
indications within the Expanded Field other than for the treatment or prevention of the common cold, without the prior written consent of ViroPharma, which consent may withheld by ViroPharma in its sole discretion and shall be subject to the Parties
reaching agreement on the terms for development and commercialization of such other indications. 

  

	 	(d)	 	Effecting License. Notwithstanding the exclusive licenses granted to Schering by ViroPharma pursuant to Article 2, Schering grants to ViroPharma a limited license under the
Patent Rights, Know-How and Trademarks in the Territory to make, have made, use, import and export, offer for sale and sell the Compound and the Products solely as permitted under Section A-3.3. The licenses granted to ViroPharma under this

  

 iv 

 Section A-2.4(d) shall include the limited right to grant sublicenses to Third Parties contracted by
ViroPharma or its Affiliates to perform services in connection with the development and/or commercialization of the Products in the Field in the Territory as permitted under Section A-3.3. Any such sublicenses shall be granted solely for the purpose
of, and only to the extent necessary to, enable such contractors to perform the relevant services for ViroPharma, shall be consistent with the terms and conditions of the License Agreement and the SaSy Agreement, and shall not include any right to
grant further sublicenses. 
  
 A-2.5  
Non-Compete. Effective as of the License Effective Date, Schering and its Affiliates shall not commercially market or manufacture for commercial marketing, directly or indirectly, any Competing Product in the Territory, where the term
“Competing Product” shall mean any pharmaceutical product for the treatment or prevention in human beings of the common cold which has as its primary mechanism of action the direct and specific inhibition of picornavirus, and that is not a
Product. The non-compete obligations set forth in this Section A-2.5 shall expire upon the last to occur of: (i) the date that is five (5) years before the expected expiration of the last to expire Patent Rights in the United States having at least
one Valid Claim that is a composition-of-matter claim to the Compound (including as such patent expiration date may be extended); or (ii) the date that is five (5) years after the First Commercial Sale of the Product in the United States. If
ViroPharma terminates the License Agreement because of the breach of a material term of the License Agreement by Schering, or if Schering terminates the License Agreement pursuant to a unilateral termination right permitted to be exercised without
cause (as defined below) and provided that there are Patent Rights in the United States having at least one Valid Claim that is a composition-of matter claim to the Compound, then the non-compete obligations set forth in this Section A-2.5 shall
survive such termination until the earlier of: (a) the two-year anniversary of the termination of the License Agreement, or (b) the expiration of the period described in the preceding sentence. If Schering terminates the License Agreement because of
the breach of a material term of the License Agreement by ViroPharma, then the non-compete obligations set forth in this Section A-2.5 shall terminate upon termination of the License Agreement. A “unilateral termination right permitted to be
exercised without cause” means a right to terminate the License Agreement after a specified notice period without the provision of any reason or explanation. 
  
 A-3  DEVELOPMENT 
  
 A-3.1   Transfer of Responsibility. Effective as of the License Effective Date, Schering shall assume responsibility for, and shall have
sole decision-making authority with respect to the development of the Compound and the Products in the Field in the Territory at Schering’s sole expense; provided that ViroPharma shall remain solely responsible for any costs related to the
Initial Studies. This shall include, without limitation, any and all additional clinical studies, toxicological studies and other development activities necessary to prepare and final NDAs for the Products in the Field in each country in the
Territory. Schering shall also be responsible for preparation, filing and maintenance of all NDAs for the Products in the Field in the Territory. Schering shall use commercially reasonable efforts to perform its obligations with respect to the

  

 v 

 development of the Products in the Field in the Territory, which efforts shall be comparable to the efforts Schering
extends with respect to its other products at a similar stage of development having substantially similar commercial potential and value. 
  
 A-3.2   Cooperation by ViroPharma. On or promptly after the License Effective Date, ViroPharma shall transfer to Schering or its
designated Affiliate all INDs for the Compound and/or the Products in the Field in the Territory. In addition, promptly after the License Effective Date ViroPharma shall, upon request, transfer to Schering any additional Know-How in the Field not
previously provided to Schering. ViroPharma shall, upon reasonable request, provide advice and consulting services to Schering on performance of all such development activities for the Products, and shall provide Schering with access to documents
and records of ViroPharma (during normal business hours) as is reasonably necessary to enable Schering to perform such development activities in a timely manner. ViroPharma shall bill Schering for the time spent by ViroPharma employees in excess of
two hundred (200) hours annually in providing such advice, consulting services or access at rates to be agreed to by the Parties. 
  
 A-3.3   Compassionate Use Programs. ViroPharma shall not make Compounds or Products available under its compassionate use programs, or
initiate any new compassionate use programs, in the Territory for any indications other than the ViroPharma Compassionate Use Indications, without Schering’s prior written approval. In addition, Schering shall have the right, exercisable at its
sole discretion at any time during the term of the License Agreement, to instruct ViroPharma to discontinue its compassionate use programs and/or to assume control over all of ViroPharma’s compassionate use programs in the Territory under which
patients are being provided access to the Compound and/or Products. Schering shall notify ViroPharma in writing in the event that Schering decides to exercise its right to terminate or take control of such compassionate use programs. Promptly
following such notice, ViroPharma shall fully cooperate with Schering and otherwise undertake any actions reasonably requested by Schering to terminate or to transfer control over the compassionate use programs to Schering or its designated
Affiliate. 
  
 A-4  COMMERCIALIZATION 
  
 A-4.1   Diligence. Except as limited by Section A-2.4(c),
effective as of the License Effective Date, Schering and its Affiliates shall, at Schering’s expense, use commercially reasonable efforts to obtain regulatory approval for and to commercialize the Product(s) in the Field in the Territory for
such indications as Schering determines are desirable. The Parties acknowledge and agree that all business decisions including, without limitation, decisions relating to Schering’s research, development, registration, manufacture, sale,
commercialization, design, pricing, distribution, marketing and promotion of Products covered under this Agreement, shall be within the sole discretion of Schering. Accordingly, Schering shall be responsible, at its cost and expense, and in its sole
judgment, for all activities that are necessary to obtain regulatory approval for the Product and any post-approval studies required as a condition of obtaining any regulatory approval for the Product in the Field in the Territory. Schering shall
also be responsible, at its cost and expense, and in its sole judgment, for determining the appropriate regulatory strategy for obtaining and maintaining all regulatory 
  

 vi 

 approvals and for obtaining and maintaining any pricing and reimbursement approvals required for the sale of the Products
in the Field in the Territory. Schering shall own all data arising out of any and all studies performed by or on behalf of Schering under this License Agreement. Each regulatory approval and each pricing and reimbursement approval shall be owned by
and held in the name of Schering or its’ designated Affiliate. ViroPharma acknowledges that Schering is in the business of developing, manufacturing and selling pharmaceutical products and nothing in this Agreement shall be construed as
restricting such business or imposing on Schering the duty to market and/or sell and exploit Compound or Products for which royalties are payable hereunder to the exclusion of, or in preference to, any other product, or in any way other than in
accordance with its normal commercial practices. 
  
 A-4.2  Excused Performance. Schering’s obligations under Section A-4.1 with respect to Products are expressly conditioned upon the continuing absence of any adverse condition or event that reasonably warrants a delay
in the development or commercialization of the Compound and/or Product including, but not limited to, an adverse condition or event relating to the safety or efficacy of the Compound and/or Product, or unfavorable labeling, pricing or pricing
reimbursement approvals, or lack of regulatory approval, and the obligation of Schering to develop or market any such Compound and/or Product shall be delayed or suspended so long as in Schering’s reasonable opinion any such condition or event
exists. 
  
 A-4.3  Diligence failure. If in
ViroPharma’s reasonable opinion, Schering fails to comply with any of its diligence obligations under Section A-4.1, then ViroPharma shall have the right to give Schering written notice thereof stating in reasonable detail the particular
failure(s). Schering shall have a period of thirty (30) days from the receipt of such notice to correct the failure or, in the event that the failure cannot be reasonably cured within a thirty (30) day period, then Schering shall initiate actions
reasonably expected to cure the failure within thirty (30) days of receiving notice and shall thereafter diligently pursue such actions to cure the failure (even if requiring longer than the thirty (30) days specified in Section A-4.3). In the event
of a dispute as to whether or not Schering has failed to exercise due diligence under Section A-4.1 or whether Schering is diligently pursuing actions reasonably expected to cure such failure under this Section A-4.3, such dispute shall be resolved
through binding arbitration in accordance with Article             . If Schering does not cure such failure, or otherwise discontinues the reasonably diligent development or
commercialization of Product in the Territory, the License Agreement shall be terminated. 
  
 A-4.4  Use of Data by Sanofi-Synthelabo. Notwithstanding any other provision of the License Agreement, Schering grants to Sanofi-Synthelabo, directly, and through ViroPharma, the exclusive right to
use all information and data developed under this License Agreement for applying for registrations of Product outside the Territory. The rights granted under this Section A-4.4 shall be subject to the payment of royalties to Schering under Section
A-6.11, and may be terminated by Schering on thirty (30) days notice of any uncured breach of Section A-6.11. 
  
 A-4.5  License of Inventions to Sanofi-Synthelabo. Notwithstanding any other provision of the License Agreement, Schering grants to
Sanofi-Synthelabo, directly, and through ViroPharma, the exclusive unrestricted right outside the Territory, to make, have made, use, market and sell products containing inventions and discoveries relating to the Compound and/or 
  

 vii 

 the Product developed under the License Agreement, including, without limitation, inventions and discoveries relating to
the manufacture of Compound and/or Product developed under the License Agreement. The rights granted under this Section A-4.5 shall be subject to the payment of royalties to Schering under Section A-6.11, and may be terminated on thirty (30) days
notice of any uncured breach of Section A-6.11. 
  
 A-4.6  Reporting. Beginning on the License Effective Date, Schering shall provide ViroPharma with semi-annual reports summarizing the status and progress of the research and development activities (including the status of
any applications for regulatory approval) for the Product. 
  
 A-5.  MANUFACTURE AND SUPPLY OF PRODUCTS 
  
 A-5.1  Technology Transfer. On or promptly after the License Effective Date, ViroPharma shall arrange for a complete technology transfer to Schering or its designated Affiliate of all available data and information related
to the manufacture of the Compound and the Product. This technology transfer shall encompass data and information related to the processes and procedures for the manufacture, testing, handling, storage, formulation and packaging of the bulk active
Compound and the finished Products, as well as the specifications and release testing for the Compound and Products and complete copies of the CMC sections for all of ViroPharma’s INDs for the Compound and/or Products. ViroPharma shall provide
Schering with samples of all available reference standards for the Compound and Products, including any known impurities and/or metabolites. ViroPharma shall also, upon request by Schering, make available personnel of ViroPharma or its Third Party
manufacturing contractors involved with the manufacture of the Compound and/or Product as reasonably necessary to advise and assist Schering or its designated Affiliate in the technology transfer, and the start-up and validation of the manufacturing
process for the Compound and/or Products. Such access to personnel shall be during normal business hours and Schering shall pay ViroPharma for the reasonable travel costs and other out-of-pocket expenses incurred by such personnel, as well as a
reasonable hourly rate to be agreed to by the Parties for the time of such personnel in excess of two hundred (200) hours annually, at Schering’s request in providing such advice and assistance. Following the successful completion of the
technology transfer provided for under this Section A-5.1, Schering (or its designated Affiliate or Third Party contractor) shall be responsible for the manufacture of all of Schering’s requirements for supplies of the Compound and the Product
for the Territory in excess of the initial supplies to be provided by ViroPharma under Section A-5.2. 
  
 A-5.2  Initial Supplies of Compound. On or promptly after the License Effective Date ViroPharma shall provide to Schering *******
kilograms of bulk active Compound. ViroPharma shall ship the Compound FCA (Incoterms 2000) to a facility to be designated in writing by Schering. ViroPharma shall include with such shipment a certificate of analysis for each batch of the Compound
certifying that it was manufactured in accordance with current Good Manufacturing Practices and meets the specifications for the Compound (as set forth in ViroPharma’s IND for the Compound). Upon receipt, Schering shall inspect the Compound and
shall notify ViroPharma of any batch(es) of the Compound that Schering determines do not meet the specifications within five (5) business days after the later of: (a) receipt of the batch, or (b) 
  

 viii 

 completion of the technology transfer described in Section A-5.1 reasonably necessary to make such determination.

  
 A-5.3  Cost of Initial Supplies. In
consideration for the supply of bulk active Compound to be provided by ViroPharma pursuant to Section A-5.2, Schering shall pay to ViroPharma six million dollars ($6,000,000) within thirty (30) days after receipt of the bulk active Compound pursuant
to Section A-5.1. To the extent that any batch(es) of such Compound are determined by the Parties not to meet specifications, the amount payable to ViroPharma under this Section A-5.3 shall be reduced by the pro-rata percentage of such amount
attributable to the non-conforming batch(es). 
  
 A-5.4  Compliant Manufacture. Schering covenants that Product will be manufactured complying with its specifications, in accordance with existing production and control requirements, for pharmaceutical products and with
current laws, rules and regulations applicable to drug substances in the Territory, including, but not limited to Good Manufacturing Practices. Schering shall identify to Sanofi-Synthelabo and ViroPharma each manufacturing facility used for the
production or packaging of Compound and Product. Schering shall provide Sanofi-Synthelabo with access during normal business hours and upon reasonable prior written request, to have an observer inspect any manufacturing facility used for the
production or packaging of Compound and Product, and to examine all technical records related to the manufacture of Compound and/or Product, and shall provide Sanofi-Synthelabo with reasonable samples of Compound and Product upon request. Schering
shall promptly notify Sanofi-Synthelabo and ViroPharma of any inspections related to the Compound or Products by the relevant government agencies having competent jurisdiction, and shall promptly inform Sanofi-Synthelabo and ViroPharma about any
material observations related to the Compound or Product. Schering shall notify Sanofi-Synthelabo and ViroPharma of any remarks which may have been made by government inspectors during their visit to any facilities involved in the manufacture of
Product, and on any appropriate actions taken in response hereto. Schering shall immediately notify Sanofi-Synthelabo and ViroPharma in writing as soon as it becomes aware of any defect or condition that may render a Compound or Product subject to
recall or product correction pursuant to any country’s law, rules and regulations. Schering shall share with Sanofi-Synthelabo and ViroPharma all data on Compound or Product complaints including but not limited to, complaints or information
regarding performance and/or allegations or reports of any adverse effects on a patient from use of Product or Compound, in accordance with an adverse events protocol to be agreed upon by the Parties. Schering shall notify Sanofi-Synthelabo and
ViroPharma of any steps taken by Schering with the regulatory authorities in the Territory in order to change, alter or modify the preparation and formulation of Product. At the request of Sanofi-Synthelabo, Schering shall enter into good-faith
negotiations to supply Compound and/or Product to Sanofi-Synthelabo, but Schering shall have no obligation to manufacture or supply any quantities of Compound and/or Products to ViroPharma or any third party, including without limitation
Sanofi-Synthelabo. 
  
 A-5.5  Trademark Usage.
Each package of Product shall include the wording “Under license from SANOFI-SYNTHELABO”, or such other statement that Sanofi-Synthelabo may reasonably request, including without limitation references to patent numbers, provided
that such wording otherwise complies with all applicable laws and regulatory requirements for such labeling. To the extent that Schering uses the Trademarks in connection with the development, 
  

 ix 

 manufacture or sale of the Compound and/or Products in the Territory, Schering shall conform to Trademark usage
guidelines provided by Sanofi-Synthelabo, and shall submit at Sanofi-Synthelabo’s request, to be made no more than two times each year, samples of packaging and promotional material bearing Trademarks, in each case to the extent such Trademarks
are owned by Sanofi-Synthelabo. In addition, Schering shall have the right to register, maintain, defend and use its own trademarks for the development, manufacture and commercialization of the Compound and/or Products in the Field in the Territory
(the “Schering Trademarks”). The Schering Trademarks shall be owned by Schering and shall not be subject to or within the scope of any rights granted under Sections A-4.4 or A-4.5. 
  
 A-6.  PAYMENTS AND ROYALTIES 
  
 A-6.1   License Fee. In partial consideration for the
licenses and other rights to be granted to Schering and its Affiliates under the License Agreement, Schering (or its designated Affiliate) shall pay a one-time license fee to ViroPharma of ten million dollars ($10,000,000) within ******* days after
the License Effective Date. 
  
 A-6.2   Milestone
Payments. Schering (or its designated Affiliate) shall pay to ViroPharma the following milestone payments: 
  

	 	(a)	 	******* upon filing and acceptance by the FDA of an NDA for the Product; 

  

	 	(b)	 	******* upon approval by the FDA of an NDA for marketing and sale of the Product in the United States for the treatment and/or prevention of the common cold;

  

	 	(c)	 	******* upon the first achievement of ******* in cumulative Net Sales of the Products in the Territory; and 

  

	 	(d)	 	******* upon the first achievement of ******* in cumulative Net Sales of the Products in the Territory. 

  
 Each of the foregoing milestone payments shall be payable once upon the first occurrence of the relevant milestone event,
and no additional payments shall be due upon any repeated occurrence of such event. Schering shall notify ViroPharma in writing within ******* after the first occurrence of each of the foregoing milestone events and payment of the relevant milestone
payment shall be due within ******* days after such notice. 
  
 A-6.3   Royalty Payments. In partial consideration for the licenses and other rights granted to Schering under the License Agreement, Schering shall pay to ViroPharma the following royalties on Net Sales of Products in the
Territory: 
  

	 	(a)	 	a royalty of ******* of Net Sales for the licenses granted under the Patent Rights (the “Patent Royalty”); and 

  

 x 

	 	(b)	 	a royalty of ******* of Net Sales for the licenses granted to Know-How and Trademarks (the “Trademark Royalty”). For the sake of clarity, the Trademark Royalty is payable
in part for the right to exclude others from using the Trademarks in the Territory and for the right to use the Know-How in support regulatory approvals for the Product in the Territory. Consequently, the Trademark Royalty shall be payable without
regard to whether Schering itself uses the Trademarks, for example, if Schering uses the Schering Trademarks, or sells a generic form of the Product. 

  
 For purposes of clarity and avoidance of doubt, the Parties acknowledge and agree that during any period of time where both Patent Royalties
and Trademark Royalties are payable on sales of a given Product in a country in the Territory, both such royalties shall be due on Net Sales of the Product in such country during such period such that Schering’s total royalty obligation with
respect to such sales during such period shall be ******* of Net Sales. None of the foregoing royalties shall be due upon the sale or other transfer among Schering, its Affiliates or permitted sublicensees, but in such cases the royalty shall be due
and calculated upon Schering’s or its Affiliates’ Net Sales to the first independent Third Party. No royalties shall accrue on the disposition of Product by Schering, its Affiliates or sublicensees as samples (promotion or otherwise), as
donations (for example, to non-profit institutions or government agencies for a non-commercial purpose, or distribution free of charge under compassionate use or indigent care programs), or for clinical studies, and such dispositions by Schering
shall not be included in the determination of Net Sales. 
  
 A-6.4   Duration of Royalty Obligations. Schering’s obligation to pay Patent Royalties under Section A-6.3 shall begin with the First Commercial Sale of a Product in the Territory and shall expire on a
country-by-country and product-by-product basis upon expiration of the last to expire of the Patent Rights in the relevant country having at least one Valid Claim. Schering’s obligation to pay Trademark Royalties under Section A-6.3 shall begin
with the First Commercial Sale of a Product in the Territory, shall survive the expiration or termination of the License Agreement, and shall endure for so long as Schering or its Affiliates sell Products in the Territory to unaffiliated Third
Parties, without regard to under which trademark or trademarks, if any, Schering sells such Products. It is further acknowledged and agreed that Schering’s obligation to pay the Trademark Royalty to ViroPharma pursuant to Section A-6.3(b) shall
not be affected or reduced in the event of any expiration, lapse or invalidation of the Trademarks in the Territory. Schering agrees that it shall not directly or indirectly initiate or undertake any legal action to seek the termination,
invalidation, revocation or any reduction of its obligation to pay the Trademark Royalty to ViroPharma pursuant to Section A-6.3(b) with respect to any sales of product in the Territory; provided, however, that this provision shall not
apply in the event of any termination of the License Agreement by Schering due to the breach of a material term of the License Agreement by ViroPharma. 
  
 A-6.5   Royalty Reporting/Payments. Following the First Commercial Sale of a Product in the Territory, Schering shall within ******* days
following the close of each calendar quarter furnish to ViroPharma a written report for the calendar quarter showing the Net Sales of Product(s) sold by Schering and/or its Affiliates in the Territory during such calendar quarter and the royalties
payable under this Agreement for such calendar quarter. Simultaneously with the 
  

 xi 

 submission of the written report, Schering shall pay to ViroPharma, for the account of Schering or the applicable
Affiliate, as the case may be, a sum equal to the aggregate royalty due for such calendar quarter calculated in accordance with this Agreement (and reconciled for any previous overpayments or underpayments). Following the First Commercial Sale of
Product, Schering shall provide ViroPharma with semi-annual reports on Schering’s marketing activities for Product. 
  
 A-6.6   Manner of Payment. The license fee, milestone payments and royalty milestone payments to be made to ViroPharma under the License
Agreement shall be paid by bank wire transfer in immediately available funds to such bank account as is designated in writing by ViroPharma from time to time. Royalties shall be deemed payable by the entity making the Net Sales from the country in
which earned in local currency and subject to foreign exchange regulations then prevailing. Royalty payments shall be made in United States dollars to the extent that free conversions to United States dollars is permitted. The rate of exchange to be
used in any such conversion from the currency in the country where such Net Sales are made shall be the rate of exchange used by Schering Corporation for reporting such sales for United States financial statement purposes. If, due to restrictions or
prohibitions imposed by national or international authority, payments cannot be made as aforesaid, the Parties shall consult with a view to finding a prompt and acceptable solution, and Schering will deal with such monies as ViroPharma may lawfully
direct at no additional out-of-pocket expense to Schering. Notwithstanding the foregoing, if royalties in any country cannot be remitted to ViroPharma for any reason within six (6) months after the end of the calendar quarter during which they are
earned, then Schering shall be obligated to deposit the royalties in a bank account in such country in the name of ViroPharma. 
  
 A-6.7   Recordkeeping. Schering and its Affiliates shall keep complete and accurate records in sufficient detail to enable the royalties
payable hereunder to be determined. Upon ******* prior written notice from ViroPharma, Schering shall permit an independent certified public accounting firm of nationally recognized standing selected by ViroPharma, at ViroPharma’s expense, to
have access during normal business hours to examine pertinent books and records of Schering and/or its Affiliates as may be reasonably necessary to verify the accuracy of the royalty reports hereunder. The examination shall be limited to pertinent
books and records for any year ending not more than ******* months prior to the date of such request. An examination under this Section A-6.7 shall not occur more than once in any calendar year. Schering may designate competitively sensitive
information, which such auditor may not disclose to ViroPharma; provided, however, that such designation shall not encompass the auditor’s conclusions. The accounting firm shall disclose to ViroPharma only whether the royalty
reports are correct or incorrect and the specific details concerning any discrepancies. No other information shall be provided to ViroPharma. All such accounting firms shall sign a confidentiality agreement (in form and substance reasonably
acceptable to Schering) as to any of Schering’s or its Affiliate’s confidential information which they are provided, or to which they have access, while conducting any audit pursuant to this Section A-6.7. ViroPharma shall be permitted to
share the results of any audit under this Section A-6.7 with Sanofi-Synthelabo provided such results are subject to appropriate confidential treatment by Sanofi-Synthelabo. 
  

 xii 

 A-6.8   Underpayments/Overpayments. If upon completion of an audit pursuant to Section
A-6.7 the accounting firm concludes that additional royalties were owed during the period audited, Schering shall pay the additional royalties within thirty (30) days of the date ViroPharma delivers to Schering such accounting firm’s written
report so correctly concluding. If such underpayment exceeds ******* of the royalty correctly due ViroPharma then the fees charged by such accounting firm for the work associated with the underpayment audit shall be paid by Schering. Any
overpayments by Schering will be credited against future royalty obligations. In the event that Schering disagrees with the audit report and the chief financial officers of Schering and ViroPharma (or their designees) fail to resolve such
disagreement, the dispute will be resolved through the dispute resolution mechanism set forth in Article             . Upon the expiration of ******* months following the end of any
calendar year, the calculation of royalties payable under this Agreement with respect to such year shall be binding and conclusive upon the Parties, and the Parties shall be released from any liability or accountability with respect to royalties for
such calendar year. 
  
 A-6.9   Withholding. If
at any time, any jurisdiction in the Territory requires the withholding of income taxes or other taxes imposed upon payments set forth in this Article A-6, Schering shall make such withholding payments as required and subtract such withholding
payments from the relevant payments, or if applicable, ViroPharma will promptly reimburse Schering or its designee(s) of the amount of such payments, it being understood that such withholding taxes are the obligation of ViroPharma. Schering shall
provide ViroPharma with documentation of such withholding and payment in a manner that is satisfactory for purposes of the U.S. Internal Revenue Service. Any withholdings paid when due hereunder shall be for the account of ViroPharma and shall not
be included in the calculation of Net Sales. Payments of withholding taxes made by Schering pursuant to this Section A-6.9 will be made based upon financial information to be provided to Schering by ViroPharma and, to the extent that such
information is incorrect or incomplete, ViroPharma shall be liable for any fine, assessment or penalty, or any deficiency, imposed by any taxing authority for any deficiency in the amount of any such withholding or the failure to make such
withholding payment. If Schering is required to pay any such deficiency, or any such fine, assessment or penalty for any such deficiency, ViroPharma shall promptly reimburse Schering for such payments, which shall not be included in the calculation
of Net Sales. 
  
 A-6.10   Third Party Royalties.
The Parties acknowledge and agree that ViroPharma shall be solely responsible at its expense for any licensee fee, milestone payments, royalties or other compensation due and owing to any Third Party in connection with intellectual property licenses
necessary for the manufacture, distribution, use and/or sale of the Compound or Formulation (as defined below) by Schering or its Affiliates in the Field in the Territory, including, without limitation, any payments due to Sanofi-Synthelabo under
the SaSy Agreement and/or any New Licenses (as defined below). In the event that the Parties determine that any additional licenses under Third Party patents or other intellectual property rights covering the Compound, the Formulation, or the
manufacture or use thereof, are required for the manufacture, distribution, use and/or sale of the Compound or the Formulation by Schering or its Affiliates in the Field in the Territory (“New Licenses”), the Parties shall meet to agree on
the appropriate scope of such New Licenses, and assign responsibilities between the Parties for negotiating such New License with the Third Party. For purposes of this Section A-6.10, “Formulation” shall mean a liquid for 
  

 xiii 

 intranasal dosing for use in the Field containing as its active ingredient the Compound, as well as *******. 

 
 A-6.11   Sanofi-Synthelabo Royalties. In consideration
for the phase III clinical studies and other development activities related to the Compound and/or the Products to be performed by Schering pursuant to Article A-3 of this License Agreement and the rights to be granted by Schering under Sections
A-4.4 and A-4.5, Schering shall be entitled to receive, and ViroPharma shall promptly pay to Schering an amount equal to ******* of all royalties or other compensation due from Sanofi-Synthelabo to ViroPharma in consideration for “Development
Work” (as defined in the SaSy Agreement), as provided in Sections 3.3 and Section 5.1(c) of the SaSy Agreement. The Parties may elect to offset any payments due from ViroPharma under this Section A-6.11 against Schering’s payment
obligations under Section A-6.1, A-6.2 and A-6.3 of this License Agreement. 
  
 A-7.  CONSISTENCY AND COMPLIANCE WITH SASY AGREEMENT 
  
 A-7.1   General. If any provision of the License Agreement would be inconsistent with, or result in a breach of the SaSy Agreement, the Parties will negotiate in good faith and shall replace such
provision with another provision that is consistent with, and does not result in a breach of the SaSy Agreement. 
  
 A-7.2   Combination Products. Schering may not market a product that contains two or more active ingredients, one of which is Compound,
except as set forth in the SaSy Agreement. 
  
 A-7.3  
Disclosure of License Agreement. Notwithstanding any confidentiality provisions in the License Agreement, Schering agrees to permit the disclosure of the License Agreement to Sanofi-Synthelabo as required under the SaSy Agreement. 

 
 A-7.4   Regularization of License Agreement and SaSy
Agreement. The Parties shall work together to establish mutually acceptable practices and arrangements with Sanofi-Synthelabo concerning: 
  

	 	(a)	 	adverse event reporting, and specifically the use of forms and systems consistent with those used by Schering; 

  

	 	(b)	 	the maintenance of a global safety database for pleconaril; 

  

	 	(c)	 	the ability of Schering to use contract manufacturers meeting pre-determined standards to manufacture Product, without further approval of Sanofi-Synthelabo; and

  

	 	(d)	 	the reciprocal disclosure between Sanofi-Synthelabo and Schering of issues concerning the manufacture either of them or their sublicensees of Product. 

  
  

 xiv 

 A-8  REPRESENTATIONS AND WARRANTIES 
  
 A-8.1   ViroPharma Warranty and Covenant. ViroPharma warrants and covenants that it will not amend the SaSy
Agreement in any way that will reduce the scope of Schering’s right existing as of the date of the License Agreement to make, have made, use, import, export, offer for sale or sell Compound or Product in the Field in the Territory, or otherwise
adversely affect the rights granted to Schering under this Agreement without Schering’s prior written consent. 
  
 A-9  INDEMNIFICATION 
  
 A-9.1   ViroPharma Indemnification. Except to the extent caused by Schering’s negligence or willful misconduct and subject to
enumerated limitations to be agreed upon by the Parties, ViroPharma shall indemnify, defend and hold harmless Schering, its Affiliates, and each of their employees, officers, directors and agents (each, a “Schering Indemnified Party”) from
and against any and all liability, loss, damage, cost, and expense (including reasonable attorneys’ fees) which the Schering Indemnified Party may incur, suffer or be required to pay resulting from or arising in connection with the claims made
or that could be made in the case Purdue Research Foundation v. Sanofi-Synthelabo, S.A., No. 03CV01924 (D.D.C. filed Sept. 16, 2003), but only to the extent that Sanofi-Synthelabo indemnifies ViroPharma against such liability, loss, damage,
cost, and expense (including reasonable attorneys’ fees). 
  
 Additional
Provisions: 
  
 The License Agreement will have additional customary terms and
provisions including, without limitation, those relating to (i) rights of termination and the effects thereof, (ii) confidentiality and publication, (iii) patent prosecution, maintenance and enforcement, (iv) representations and warranties of each
Party in addition to those described in Section A-8, (v) indemnification provisions in addition to those described in Section A-9, (vi) dispute resolution mechanisms and miscellaneous provisions relating to assignment, governing law, export control,
force majeure and notices. 
  
  

 xv 

 Exhibit B 
  

 
 Arbitration Provisions 
  
 1.)     Within ten (10) business days after the receipt
of the notice provided for in Section 11.4(a) of this Agreement, each Party shall appoint an independent expert, knowledgeable in the field concerning the Dispute (e.g., an expert in the field of drug delivery and/or formulation technology), to
serve on the special arbitration panel (the “Panel”). The two independent experts so appointed by the Parties, shall, within ten (10) business days thereafter, appoint a neutral third independent expert, knowledgeable in the field
concerning the Dispute. Such neutral third independent expert shall serve as the chairperson of the Panel. Each of the members of the Panel shall be required to sign a secrecy agreement, acceptable in form to both Parties, with respect to any
information provided by either Party during the arbitration procedure. 
  
 2.)     Within five (5) business days after the chairperson of the Panel is appointed, each Party shall submit to each member of the Panel, and to the other Party, a written statement setting forth the relevant facts
with respect to the Dispute and arguments supporting such Party’s position with respect to the resolution of the Dispute. 
  
 3.)     Within five (5) business days after such written statements are provided to the Panel, the Panel and appropriate
representatives of each Party shall meet so that the Parties can present oral arguments to the Panel, and the Panel can have the opportunity to ask questions of the Parties. The location of such meeting shall be in New York, New York. Each Party
shall have two (2) hours to present its arguments to the Panel and thirty (30) additional minutes to rebut the arguments made by the other Party. The Party requesting the arbitration shall be the first to present its oral argument to the Panel.

  
 4)     Within five (5) business days after
such meeting, the Panel shall render a decision on the Dispute, which decision shall be reduced to writing by the chairperson of the Panel and signed by each member of the Panel. The chairperson of the Panel shall be responsible for immediately
providing a copy of the written decision to each Party. Such decision shall be binding with respect to any Disputes under this Agreement. 
  
 5)     Each Party shall be responsible for its own costs (including, without limitation, reasonable attorneys fees) and expenses
incurred in such arbitration procedures and the cost of the Panel shall be shared equally by the Parties; provided, however, that if the Panel determines that the action of any Party was arbitrary, frivolous or in bad faith, the Panel may award such
costs and expenses to the prevailing Party. 
  
 6)     The arbitration proceeding shall be confidential and, except as required by law, neither Party shall make (or instruct the Panel to make) any public announcement with respect to the proceedings or decision of the
Panel without the prior written consent of the other Party. The existence of any dispute submitted to arbitration, and the award of the Panel, shall be kept in confidence by the Parties and the Panel, except as required in connection with the
enforcement of such award or as otherwise required by applicable law. 
  

 B-1 

 7)     For the purposes of these arbitration provisions, the Parties acknowledge
their diversity and agree to accept the jurisdiction of the Federal District Courts in New York, New York for the purposes of enforcing awards entered pursuant to these arbitration provisions and for enforcing the agreements reflected in this
Paragraph 7. 
  
 8)     Nothing contained
herein shall be construed to permit the Panel or any court or any other forum to award punitive, exemplary or any similar damages. By entering into the Agreement and exercising their rights to arbitrate, the Parties expressly waive any claim for
punitive, exemplary or any similar damages. The only damages recoverable under this Agreement are compensatory damages. 
  
 9)     The procedures specified herein shall be the sole and exclusive procedures for the resolution of disputes between the Parties
which are expressly identified for resolution in accordance with these arbitration provisions. 
  

 B-2Registration Rights Agreement dated December 9, 2003

 EXHIBIT 4.2 
  

101⁄2% Senior Notes due 2010 
  
 REGISTRATION RIGHTS AGREEMENT 
  
 Dated as of December 9, 2003 
 by and
among 
  
 Insight Midwest, L.P. 
 Insight Capital, Inc. 
  
 and 
  
 BANC OF AMERICA SECURITIES LLC 
 BNY CAPITAL MARKETS, INC. 
 J.P. MORGAN SECURITIES INC. 
 MORGAN
STANLEY & CO. INCORPORATED 
 TD SECURITIES (USA) INC. 
  

 This Registration Rights Agreement (this “Agreement”) is made and entered into as
of December 9, 2003 by and among Insight Midwest, L.P., a Delaware limited partnership (the “Company”), Insight Capital, Inc., a Delaware corporation (together with the Company, the “Issuers”), and
Banc of America Securities LLC, BNY Capital Markets, Inc., J.P. Morgan Securities Inc., Morgan Stanley & Co. Incorporated and TD Securities (USA) Inc. (the “Initial Purchasers”), has agreed to purchase the Issuers’
101⁄2 % Series A Senior Notes due 2010 (the “Series A Notes”) pursuant to the Purchase Agreement (as defined below). 
  
 This Agreement is made pursuant to the Purchase Agreement, dated December 4, 2003 (the “Purchase Agreement”), by and among the
Issuers and the Initial Purchasers. In order to induce the Initial Purchasers to purchase the Series A Notes, the Issuers have agreed to provide the registration rights set forth in this Agreement. The execution and delivery of this Agreement is a
condition to the obligations of the Initial Purchasers set forth in Section 3 of the Purchase Agreement. Capitalized terms used herein and not otherwise defined shall have the meaning assigned to them in the Indenture, dated November 6, 2000,
between the Issuers and The Bank of New York, as trustee (the “Trustee”), relating to the Series A Notes and the Series B Notes (the “Indenture”). 
  
 The parties hereby agree as follows: 
  

	1.	DEFINITIONS 

  
 As used in this Agreement, the following capitalized terms shall have the following meanings: 
  
 Act: The Securities Act of 1933, as amended. 
  
 Affiliate: As defined in Rule 144 of the Act. 
  
 Broker-Dealer: Any broker or dealer registered under the
Exchange Act. 
  
 Certificated Securities:
Definitive Notes, as defined in the Indenture. 
  
 Closing
Date: The date hereof. 
  
 Commission: The
Securities and Exchange Commission. 
  
 Consummate:
An Exchange Offer shall be deemed “Consummated” for purposes of this Agreement upon the occurrence of (a) the filing and effectiveness under the Act of the Exchange Offer Registration Statement relating to the Series B Notes to be issued
in the Exchange Offer, (b) the maintenance of such Exchange Offer Registration Statement continuously effective and the keeping of the Exchange Offer open for a period not less than the period required pursuant to Section 3(b) hereof and (c) the
delivery by the Issuers to the Registrar under the Indenture of Series B Notes in the same aggregate principal amount as the aggregate principal amount of Series A Notes tendered by Holders thereof pursuant to the Exchange Offer. 
  
 Consummation Deadline: As defined in Section 3(b) hereof.

  
 Effectiveness Deadline: As defined in Section
3(a) and 4(a) hereof. 
  

 1 

 Exchange Act: The Securities Exchange Act of 1934, as amended. 
  
 Exchange Offer: The exchange and issuance by the Issuers of a
principal amount of Series B Notes (which shall be registered pursuant to the Exchange Offer Registration Statement) equal to the outstanding principal amount of Series A Notes that are tendered by such Holders in connection with such exchange and
issuance. 
  
 Exchange Offer Registration Statement:
The Registration Statement relating to the Exchange Offer, including the related Prospectus. 
  
 Exempt Resales: The transactions in which the Initial Purchasers proposes to sell the Series A Notes to certain “qualified institutional buyers,” as such term is defined in Rule 144A under the
Act and pursuant to Regulation S under the Act. 
  
 Filing
Deadline: As defined in Sections 3(a) and 4(a) hereof. 
  
 Holders: As defined in Section 2 hereof. 
  
 Prospectus: The prospectus included in a Registration Statement at the time such Registration Statement is declared effective, as amended or supplemented by any prospectus supplement and by all other amendments thereto,
including post-effective amendments, and all material incorporated by reference into such Prospectus. 
  
 Recommencement Date: As defined in Section 6(d) hereof. 
  
 Registration Default: As defined in Section 5 hereof. 
  
 Registration Statement: Any registration statement of the
Issuers relating to (a) an offering of Series B Notes pursuant to an Exchange Offer or (b) the registration for resale of Transfer Restricted Securities pursuant to the Shelf Registration Statement, in each case, (i) that is filed pursuant to the
provisions of this Agreement and (ii) including the Prospectus included therein, all amendments and supplements thereto (including post-effective amendments) and all exhibits and material incorporated by reference therein. 
  
 Regulation S: Regulation S promulgated under the Act.

  
 Rule 144: Rule 144 promulgated under the Act.

  
 Series B Notes: The Issuers’ 101⁄2%
Series B Senior Notes due 2010 to be issued pursuant to the Indenture (i) in the Exchange Offer or (ii) as contemplated by Section 4 hereof. 
  
 Shelf Registration Statement: As defined in Section 4 hereof. 
  
 Suspension Notice: As defined in Section 6(d) hereof. 
  
 TIA: The Trust Indenture Act of 1939 (15 U.S.C. Section
77aaa-77bbbb) as in effect on the date of the Indenture. 
  
 Transfer Restricted Securities: Each (A) Series A Note, until the earliest to occur of (i) the date on which such Series A Note is exchanged in the Exchange Offer for a Series B Note 

  

 2 

 
which is entitled to be resold to the public by the Holder thereof without complying with the prospectus delivery requirements of the Act, (ii) the date on
which such Series A Note has been disposed of in accordance with a Shelf Registration Statement (and the purchasers thereof have been issued Series B Notes), or (iii) the date on which such Series A Note is distributed to the public pursuant to Rule
144 under the Act and each (B) Series B Note held by a Broker-Dealer until the date on which such Series B Note is disposed of by a Broker-Dealer pursuant to the “Plan of Distribution” contemplated by the Exchange Offer Registration
Statement (including the delivery of the Prospectus contained therein). 
  

	2.	HOLDERS 

  
 A Person is deemed to be a holder of Transfer Restricted Securities (each, a “Holder”) whenever such Person owns Transfer
Restricted Securities. 
  

	3.	REGISTERED EXCHANGE OFFER 

  
 (a) Unless the Exchange Offer shall not be permitted by applicable federal law (after the procedures set forth in Section 6(a)(i) below have been complied
with), the Issuers shall (i) cause the Exchange Offer Registration Statement to be filed with the Commission as soon as practicable after the Closing Date, but in no event later than 180 days after the Closing Date (such 180th day being the
“Filing Deadline”), (ii) use their reasonable best efforts to cause such Exchange Offer Registration Statement to become effective at the earliest possible time, but in no event later than 365 days after the Closing Date
(such 365th day being the “Effectiveness Deadline”), (iii) in connection with the foregoing, (A) file all pre-effective amendments to such Exchange Offer Registration Statement as may be necessary in order to cause it to
become effective, (B) file, if applicable, a post-effective amendment to such Exchange Offer Registration Statement pursuant to Rule 430A under the Act and (C) cause all necessary filings, if any, in connection with the registration and
qualification of the Series B Notes to be made under the Blue Sky laws of such jurisdictions as are necessary to permit Consummation of the Exchange Offer, and (iv) upon the effectiveness of such Exchange Offer Registration Statement, commence and
Consummate the Exchange Offer. The Exchange Offer shall be on the appropriate form permitting (i) registration of the Series B Notes to be offered in exchange for the Series A Notes that are Transfer Restricted Securities and (ii) resales of Series
B Notes by Broker-Dealers that tendered into the Exchange Offer Series A Notes that such Broker-Dealer acquired for its own account as a result of market making activities or other trading activities (other than Series A Notes acquired directly from
the Issuers or any their Affiliates) as contemplated by Section 3(c) below. 
  
 (b) The Issuers shall use their reasonable best efforts to cause the Exchange Offer Registration Statement to be effective continuously, and shall keep the Exchange Offer open for a period of not less than the minimum
period required under applicable federal and state securities laws to Consummate the Exchange Offer; provided, however, that in no event shall such period be less than 20 Business Days. The Issuers shall cause the Exchange Offer to comply
with all applicable federal and state securities laws. No securities other than the Series B Notes shall be included in the Exchange Offer Registration Statement. The Issuers shall use their reasonable best efforts to cause the Exchange Offer to be
Consummated on the earliest practicable date after the Exchange Offer Registration Statement has become effective, but in no event later than 30 business days thereafter or such later date that may be required by federal securities laws (such
30th or later day being the “Consummation Deadline”). 
  

 3 

 (c) The Issuers shall include a “Plan of Distribution” section in the Prospectus contained in
the Exchange Offer Registration Statement and indicate therein that any Broker-Dealer who holds Transfer Restricted Securities that were acquired for the account of such Broker-Dealer as a result of market-making activities or other trading
activities (other than Series A Notes acquired directly from the Issuers or any Affiliate of the Issuers), may exchange such Transfer Restricted Securities pursuant to the Exchange Offer. Such “Plan of Distribution” section shall also
contain all other information with respect to such sales by such Broker-Dealers that the Commission may require in order to permit such sales pursuant thereto, but such “Plan of Distribution” shall not name any such Broker-Dealer or
disclose the amount of Transfer Restricted Securities held by any such Broker-Dealer, except to the extent required by the Commission as a result of a change in policy, rules or regulations after the date of this Agreement. See the Shearman &
Sterling no-action letter (available July 2, 1993). 
  
 Because such Broker-Dealer may be deemed to be an “underwriter” within the meaning of the Act and must, therefore, deliver a prospectus meeting the requirements of the Act in connection with its initial sale of any Series B Notes
received by such Broker-Dealer in the Exchange Offer, the Issuers shall permit the use of the Prospectus contained in the Exchange Offer Registration Statement by such Broker-Dealer to satisfy such prospectus delivery requirement. To the extent
necessary to ensure that the prospectus contained in the Exchange Offer Registration Statement is available for sales of Series B Notes by Broker-Dealers, the Issuers agree to use their reasonable best efforts to keep the Exchange Offer Registration
Statement continuously effective, supplemented, amended and current as required by and subject to the provisions of Section 6(a) and (c) hereof and in conformity with the requirements of this Agreement, the Act and the policies, rules and
regulations of the Commission as announced from time to time, for a period of 180 days from the Consummation Deadline or such shorter period as will terminate when all Transfer Restricted Securities covered by such Registration Statement have been
sold pursuant thereto. The Issuers shall provide sufficient copies of the latest version of such Prospectus to such Broker-Dealers, promptly upon request, and in no event later than one day after such request, at any time during such period.

  

	4.	SHELF REGISTRATION 

  
 (a) Shelf Registration. If (i) the Exchange Offer is not permitted by applicable law (after the Issuers have complied with the procedures set forth
in Section 6(a)(i) below) or (ii) if any Holder of Transfer Restricted Securities shall notify the Issuers within 20 Business Days following the Consummation Deadline that (A) such Holder was prohibited by law or Commission policy from participating
in the Exchange Offer or (B) such Holder may not resell the Series B Notes acquired by it in the Exchange Offer to the public without delivering a prospectus and the Prospectus contained in the Exchange Offer Registration Statement is not
appropriate or available for such resales by such Holder or (C) such Holder is a Broker-Dealer and holds Series A Notes acquired directly from the Issuers or any of their Affiliates, then the Issuers shall: 
  
 (x) use their reasonable best efforts to cause to be filed, on or prior to 30
days after the earlier of (i) the date on which the Issuers determine that the Exchange Offer Registration Statement cannot be filed as a result of clause (a)(i) above and (ii) the date on which the Issuers receive the notice specified in clause
(a)(ii) above, (such earlier date, the “Filing Deadline”), a shelf registration statement pursuant to Rule 415 under the Act (which may be an amendment to the Exchange Offer 

  

 4 

 
Registration Statement (the “Shelf Registration Statement”)), relating to all Transfer Restricted Securities, and 
  
 (y) use their reasonable best efforts to cause such Shelf Registration
Statement to become effective on or prior to 90 days after the Filing Deadline for the Shelf Registration Statement (such 90th day the “Effectiveness Deadline”); 
  
 provided that in no event shall the Filing Deadline and Effectiveness Deadline under Section 4(a) be earlier than the Filing
Deadline and Effectiveness Deadline under Section 3(a). 
  
 If,
after the Issuers have filed an Exchange Offer Registration Statement that satisfies the requirements of Section 3(a) above, the Issuers are required to file and make effective a Shelf Registration Statement solely because the Exchange Offer is not
permitted under applicable federal law (i.e., clause (a)(i) above), then the filing of the Exchange Offer Registration Statement shall be deemed to satisfy the requirements of clause (x) above; provided that, in such event, the Issuers shall
remain obligated to meet the Effectiveness Deadline set forth in clause (y). 
  
 To the extent necessary to ensure that the Shelf Registration Statement is available for sales of Transfer Restricted Securities by the Holders thereof entitled to the benefit of this Section 4(a) and the other
securities required to be registered therein pursuant to Section 6(b)(ii) hereof, the Issuers shall use their reasonable best efforts to keep any Shelf Registration Statement required by this Section 4(a) continuously effective, supplemented,
amended and current as required by and subject to the provisions of Sections 6(b) and (c) hereof and in conformity with the requirements of this Agreement, the Act and the policies, rules and regulations of the Commission as announced from time to
time, for a period of at least two years (as extended pursuant to Section 6(c)(i)) following the Closing Date, or such shorter period as will terminate when all Transfer Restricted Securities covered by such Shelf Registration Statement have been
sold pursuant thereto. 
  
 (b) Provision by Holders of Certain
Information in Connection with the Shelf Registration Statement. No Holder of Transfer Restricted Securities may include any of its Transfer Restricted Securities in any Shelf Registration Statement pursuant to this Agreement unless and until
such Holder furnishes to the Issuers in writing, within 20 days after receipt of a request therefor, the information specified in Item 507 or 508 of Regulation S-K, as applicable, of the Act for use in connection with any Shelf Registration
Statement or Prospectus or preliminary Prospectus included therein. No Holder of Transfer Restricted Securities shall be entitled to liquidated damages pursuant to Section 5 hereof unless and until such Holder shall have provided all such
information. Each selling Holder agrees to promptly furnish additional information required to be disclosed in order to make the information previously furnished to the Issuers by such Holder not materially misleading. 
  

	5.	LIQUIDATED DAMAGES 

  
 If (i) any Registration Statement required by this Agreement is not filed with the Commission on or prior to the applicable Filing Deadline, (ii) any such
Registration Statement has not been declared effective by the Commission on or prior to the applicable Effectiveness Deadline, (iii) the Exchange Offer has not been Consummated on or prior to the Consummation Deadline or (iv) any Registration
Statement required by this Agreement is filed and declared effective but shall thereafter cease to be effective or fail to be usable for its intended purpose without being succeeded immediately by a post-effective amendment to such Registration

  

 5 

 
Statement that cures such failure and that is itself declared effective immediately (each such event referred to in clauses (i) through (iv), a
“Registration Default”), then the Issuers hereby jointly and severally agree to pay to each Holder of Transfer Restricted Securities affected thereby liquidated damages in an amount equal to $.05 per week per $1,000 in
principal amount of Transfer Restricted Securities held by such Holder for each week or portion thereof that the Registration Default continues for the first 90-day period immediately following the occurrence of such Registration Default. The amount
of the liquidated damages shall increase by an additional $.05 per week per $1,000 in principal amount of Transfer Restricted Securities with respect to each subsequent 90-day period until all Registration Defaults have been cured, up to a maximum
amount of liquidated damages of $.50 per week per $1,000 in principal amount of Transfer Restricted Securities; provided that the Issuers shall in no event be required to pay liquidated damages for more than one Registration Default at any
given time. Notwithstanding anything to the contrary set forth herein, (1) upon filing of the Exchange Offer Registration Statement (and/or, if applicable, the Shelf Registration Statement), in the case of (i) above, (2) upon the effectiveness of
the Exchange Offer Registration Statement (and/or, if applicable, the Shelf Registration Statement), in the case of (ii) above, (3) upon Consummation of the Exchange Offer, in the case of (iii) above, or (4) upon the filing of a post-effective
amendment to the Registration Statement or an additional Registration Statement that causes the Exchange Offer Registration Statement (and/or, if applicable, the Shelf Registration Statement) to again be declared effective or made usable in the case
of (iv) above, the liquidated damages payable with respect to the Transfer Restricted Securities as a result of such clause (i), (ii), (iii) or (iv), as applicable, shall cease. 
  
 All accrued liquidated damages shall be paid to the Holders entitled thereto, in the manner provided for the payment of
interest in the Indenture, on each Interest Payment Date, as more fully set forth in the Indenture and the Notes. Notwithstanding the fact that any securities for which liquidated damages are due cease to be Transfer Restricted Securities, all
obligations of the Issuers to pay liquidated damages with respect to securities shall survive until such time as such obligations with respect to such securities shall have been satisfied in full. 
  

	6.	REGISTRATION PROCEDURES 

  
 (a) Exchange Offer Registration Statement. In connection with the Exchange Offer, the Issuers shall (x) comply with all applicable provisions of
Section 6(c) below, (y) use their reasonable best efforts to effect such exchange and to permit the resale of Series B Notes by Broker-Dealers that tendered in the Exchange Offer Series A Notes that such Broker-Dealer acquired for its own account as
a result of its market making activities or other trading activities (other than Series A Notes acquired directly from the Issuers or any of their Affiliates) being sold in accordance with the intended method or methods of distribution thereof, and
(z) comply with all of the following provisions: 
  
 (i) If, following the date hereof there has been announced a change in Commission policy with respect to exchange offers such as the Exchange Offer, that in the reasonable opinion of counsel to the Issuers raises a substantial question as
to whether the Exchange Offer is permitted by applicable federal law, the Issuers hereby agree to seek a no-action letter or other favorable decision from the Commission allowing the Issuers to Consummate an Exchange Offer for such Transfer
Restricted Securities. The Issuers hereby agree to pursue the issuance of such a decision to the Commission staff level. In connection with the foregoing, 

  

 6 

	 	 
the Issuers hereby agree to take all such other actions as may be requested by the Commission or otherwise required in connection with the issuance of such
decision, including without limitation (A) participating in telephonic conferences with the Commission, (B) delivering to the Commission staff an analysis prepared by counsel to the Issuers setting forth the legal bases, if any, upon which such
counsel has concluded that such an Exchange Offer should be permitted and (C) diligently pursuing a resolution (which need not be favorable) by the Commission staff. 

  
 (ii) As a condition to its participation in the Exchange Offer, each Holder of Transfer Restricted
Securities (including, without limitation, any Holder who is a Broker-Dealer) shall furnish, upon the request of the Issuers, prior to the Consummation of the Exchange Offer, a written representation to the Issuers (which may be contained in the
letter of transmittal contemplated by the Exchange Offer Registration Statement) to the effect that (A) it is not an Affiliate of the Issuers, (B) it is not engaged in, and does not intend to engage in, and has no arrangement or understanding with
any person to participate in, a distribution of the Series B Notes to be issued in the Exchange Offer and (C) it is acquiring the Series B Notes in its ordinary course of business. As a condition to its participation in the Exchange Offer, each
Holder using the Exchange Offer to participate in a distribution of the Series B Notes shall acknowledge and agree that, if the resales are of Series B Notes obtained by such Holder in exchange for Series A Notes acquired directly from the Issuers
or an Affiliate thereof, it (1) could not, under Commission policy as in effect on the date of this Agreement, rely on the position of the Commission enunciated in Morgan Stanley and Co., Inc. (available June 5, 1991) and Exxon Capital
Holdings Corporation (available May 13, 1988), as interpreted in the Commission’s letter to Shearman & Sterling dated July 2, 1993, and similar no-action letters (including, if applicable, any no-action letter obtained pursuant
to clause (i) above), and (2) must comply with the registration and prospectus delivery requirements of the Act in connection with a secondary resale transaction and that such a secondary resale transaction must be covered by an effective
registration statement containing the selling security holder information required by Item 507 or 508, as applicable, of Regulation S-K. 
  
 (iii) Prior to effectiveness of the Exchange Offer Registration Statement, the Issuers shall provide a supplemental letter to the
Commission (A) stating that the Issuers are registering the Exchange Offer in reliance on the position of the Commission enunciated in Exxon Capital Holdings Corporation (available May 13, 1988), Morgan Stanley and Co., Inc. (available
June 5, 1991) as interpreted in the Commission’s letter to Shearman & Sterling dated July 2, 1993, and, if applicable, any no-action letter obtained pursuant to clause (i) above, (B) including a representation that neither Issuer has
entered into any arrangement or understanding with any Person to distribute the Series B Notes to be received in the Exchange Offer and that, to the best of the Issuers’ information and belief, each Holder participating in the Exchange Offer is
acquiring the Series B Notes in its ordinary course of business and has no arrangement or understanding with any Person to participate in the distribution of the Series B Notes received in the Exchange Offer and (C) any other undertaking or
representation required by the 

  

 7 

 
Commission as set forth in any no-action letter obtained pursuant to clause (i) above, if applicable. 
  
 (b) Shelf Registration Statement. In connection with the Shelf
Registration Statement, the Issuers shall: 
  
 (i) comply with all the provisions of Section 6(c) below and use their reasonable best efforts to effect such registration to permit the sale of the Transfer Restricted Securities being sold in accordance with the intended method or methods
of distribution thereof (as indicated in the information furnished to the Issuers pursuant to Section 4(b) hereof), and pursuant thereto the Issuers will prepare and file with the Commission a Registration Statement relating to the registration on
any appropriate form under the Act, which form shall be available for the sale of the Transfer Restricted Securities in accordance with the intended method or methods of distribution thereof within the time periods and otherwise in accordance with
the provisions hereof, and 
  
 (ii) issue, upon
the request of any Holder or purchaser of Series A Notes covered by any Shelf Registration Statement contemplated by this Agreement, Series B Notes having an aggregate principal amount equal to the aggregate principal amount of Series A Notes sold
pursuant to the Shelf Registration Statement and surrendered to the Issuers for cancellation; the Issuers shall register Series B Notes on the Shelf Registration Statement for this purpose and issue the Series B Notes to the purchaser(s) of
securities subject to the Shelf Registration Statement in the names as such purchaser(s) shall designate. 
  
 (c) General Provisions. In connection with any Registration Statement and any related Prospectus required by this Agreement, the Issuers shall:

  
 (i) use their reasonable best efforts to keep
such Registration Statement continuously effective and provide all requisite financial statements for the period specified in Section 3 or 4 of this Agreement, as applicable. Upon the occurrence of any event that would cause any such Registration
Statement or the Prospectus contained therein (A) to contain an untrue statement of material fact or omit to state any material fact necessary to make the statements therein not misleading or (B) not to be effective and usable for resale of Transfer
Restricted Securities during the period required by this Agreement, the Issuers shall file promptly an appropriate amendment to such Registration Statement curing such defect, and, if Commission review is required, use their reasonable best efforts
to cause such amendment to be declared effective as soon as practicable; 
  
 (ii) prepare and file with the Commission such amendments and post-effective amendments to the applicable Registration Statement as may be necessary to keep such Registration Statement effective for the applicable
period set forth in Section 3 or 4 hereof, as the case may be; cause the Prospectus to be supplemented by any required Prospectus supplement, and as so supplemented to be filed pursuant to Rule 424 under the Act, and to comply fully with Rules 424,
430A and 462, as applicable, under the Act in a timely manner; and comply with those provisions of the Act that are applicable to the Issuers with respect to the 

  

 8 

	 	 
disposition of all securities covered by such Registration Statement during the applicable period in accordance with the intended method or methods of
distribution by the sellers thereof set forth in such Registration Statement or supplement to the Prospectus; 

  
 (iii) advise each Holder promptly and, if requested by such Holder, confirm such advice in writing, (A) when the Prospectus or any
Prospectus supplement or post-effective amendment has been filed, and, with respect to any applicable Registration Statement or any post-effective amendment thereto, when the same has become effective, (B) of any request by the Commission for
amendments to the Registration Statement or supplements to the Prospectus or for additional information relating thereto, (C) of the issuance by the Commission of any stop order suspending the effectiveness of the Registration Statement under the
Act or of the suspension by any state securities commission of the qualification of the Transfer Restricted Securities for offering or sale in any jurisdiction, or the initiation of any proceeding for any of the preceding purposes, and (D) of the
existence of any fact or the happening of any event that makes any statement of a material fact made in the Registration Statement, the Prospectus, any amendment or supplement thereto or any document incorporated by reference therein untrue, or that
requires the making of any additions to or changes in the Registration Statement in order to make the statements therein not misleading, or that requires the making of any additions to or changes in the Prospectus in order to make the statements
therein, in the light of the circumstances under which they were made, not misleading. If at any time the Commission shall issue any stop order suspending the effectiveness of the Registration Statement, or any state securities commission or other
regulatory authority shall issue an order suspending the qualification or exemption from qualification of the Transfer Restricted Securities under state securities or Blue Sky laws, the Issuers shall use their reasonable best efforts to obtain the
withdrawal or lifting of such order at the earliest possible time; 
  
 (iv) subject to Section 6(c)(i), if any fact or event contemplated by Section 6(c)(iii)(D) above shall exist or have occurred, prepare a supplement or post-effective amendment to the Registration Statement or related
Prospectus or any document incorporated therein by reference or file any other required document so that, as thereafter delivered to the purchasers of Transfer Restricted Securities, the Prospectus will not contain an untrue statement of a material
fact or omit to state any material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading; 
  

(v) if requested by a Holder, furnish to such Holder in connection with such exchange or sale, if any, before filing with the
Commission, copies of any Registration Statement or any Prospectus included therein or any amendments or supplements to any such Registration Statement or Prospectus (including all documents incorporated by reference after the initial filing of such
Registration Statement), which documents will be subject to the review and comment of such Holder in connection with such sale, if any, for a period of at least two Business Days, and the Issuers will not file any such Registration Statement or
Prospectus or any amendment or supplement to any such Registration Statement or Prospectus 

  

 9 

 
(including all such documents incorporated by reference) to which such Holder shall reasonably object within two Business Days after the receipt thereof. A
Holder shall be deemed to have reasonably objected to such filing if such Registration Statement, amendment,
Prospectus or supplement, as applicable, as proposed to be filed, contains an untrue statement of a material fact or omit to state any material fact necessary to make the statements therein not misleading or fails to comply with the applicable
requirements of the Act; 
  
 (vi) if requested by
a Holder, promptly prior to the filing of any document that is to be incorporated by reference into a Registration Statement or Prospectus, provide copies of such document to such Holder in connection with such exchange or sale, if any, make the
Issuers’ representatives available for discussion of such document and other customary due diligence matters, and include such information in such document prior to the filing thereof as such Holder may reasonably request; 
  
 (vii) make available, at reasonable times, for inspection by
each underwriter and any attorney or accountant retained by such underwriters, all financial and other records, pertinent corporate documents of the Issuers and cause the Issuers’ officers, directors and employees to supply all information
reasonably requested by any such underwriters, attorney or accountant in connection with such Registration Statement or any post-effective amendment thereto subsequent to the filing thereof and prior to its effectiveness; 
  
 (viii) if requested by any Holder in connection with such
exchange or sale, promptly include in any Registration Statement or Prospectus, pursuant to a supplement or post-effective amendment if necessary, such information as such Holders may reasonably request to have included therein, including, without
limitation, information relating to the “Plan of Distribution” of the Transfer Restricted Securities; and make all required filings of such Prospectus supplement or post-effective amendment as soon as practicable after the Issuers are
notified of the matters to be included in such Prospectus supplement or post-effective amendment; 
  
 (ix) furnish to each Holder in connection with such exchange or sale, without charge, at least one copy of the Registration Statement, as
first filed with the Commission, and of each amendment thereto, including all documents incorporated by reference therein and all exhibits (including exhibits incorporated therein by reference); 
  
 (x) deliver to each Holder without charge, as many copies of
the Prospectus (including each preliminary prospectus) and any amendment or supplement thereto as such Persons reasonably may request; the Issuers hereby consent to the use (in accordance with law) of the Prospectus and any amendment or supplement
thereto by each selling Holder in connection with the offering and the sale of the Transfer Restricted Securities covered by the Prospectus or any amendment or supplement thereto; 
  

 10 

 (xi) upon the request of any Holder, enter into such agreements (including underwriting
agreements) and make such representations and warranties and take all such other actions in connection therewith in order to expedite or facilitate the disposition of the Transfer Restricted Securities pursuant to any applicable Registration
Statement contemplated by this Agreement as may be reasonably requested by any Holder in connection with any sale or resale pursuant to any applicable Registration Statement. In such connection the Issuers shall: 
  
 (A) upon request of any underwriter, furnish (or in the case
of paragraphs (2) and (3), use its reasonable best efforts to cause to be furnished) to such underwriter, upon Consummation of the Exchange Offer or upon the effectiveness of the Shelf Registration Statement, as the case may be: 
  
 (1) a certificate, dated such date, signed by the President
and the Chief Financial Officer of each of the Issuers, confirming, as of the date thereof, the matters set forth in Sections 6(ff), 9(a) and 9(b) of the Purchase Agreement and such other similar matters as such underwriter may reasonably request;

  
 (2) an opinion, dated the date of
Consummation of the Exchange Offer or the date of effectiveness of the Shelf Registration Statement, as the case may be, of counsel for the Issuers covering matters similar to those set forth in paragraph (e) of Section 9 of the Purchase Agreement
and such other matters as such underwriter may reasonably request, and in any event including a statement to the effect that such counsel has participated in conferences with officers and other representatives of each of the Issuers, representatives
of the independent public accountants for the Issuers and has considered the matters required to be stated therein and the statements contained therein, although such counsel has not independently verified the accuracy, completeness or fairness of
such statements; and that such counsel advises that, on the basis of the foregoing, no facts came to such counsel’s attention that caused such counsel to believe that the applicable Registration Statement, at the time such Registration
Statement or any post-effective amendment thereto became effective and, in the case of the Exchange Offer Registration Statement, as of the date of Consummation of the Exchange Offer, contained an untrue statement of a material fact or omitted to
state a material fact required to be stated therein or necessary to make the statements therein not misleading, or that the Prospectus contained in such Registration Statement as of its date and, in the case of the opinion dated the date of
Consummation of the Exchange Offer, as of the date of Consummation, contained an untrue statement of a material fact or omitted to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which
they were made, not misleading. Without limiting the foregoing, such counsel may state further that such counsel assumes no responsibility for, and has not independently verified, the accuracy, completeness or fairness of the financial statements,
schedules and other financial data included in any Registration Statement contemplated by this Agreement or the related Prospectus; and 
  

 11 

 (3) a customary comfort letter, dated the date of Consummation of the Exchange Offer, or
as of the date of effectiveness of the Shelf Registration Statement, as the case may be, from the Issuers’ independent accountants, in the customary form and covering matters of the type customarily covered in comfort letters to underwriters in
connection with underwritten offerings, and affirming the matters set forth in the comfort letters delivered pursuant to Section 9(h) of the Purchase Agreement; and 
  
 (B) deliver such other documents and certificates as may be reasonably requested by the underwriter to
evidence compliance with the matters covered in clause (A) above and with any customary conditions contained in any agreement entered into by the Issuers pursuant to this clause (xi); 
  
 (xii) prior to any public offering of Transfer Restricted Securities, cooperate with the selling Holders and
their counsel in connection with the registration and qualification of the Transfer Restricted Securities under the securities or Blue Sky laws of such jurisdictions as the selling Holders may reasonably request and do any and all other acts or
things necessary or advisable to enable the disposition in such jurisdictions of the Transfer Restricted Securities covered by the applicable Registration Statement; provided, however, that neither Issuer shall be required to register or
qualify as a foreign corporation, or limited partnership, as the case may be, where it is not now so qualified or to take any action that would subject it to the service of process in suits or to taxation, other than as to matters and transactions
relating to the Registration Statement, in any jurisdiction where it is not now so subject; 
  
 (xiii) in connection with any sale of Transfer Restricted Securities that will result in such securities no longer being Transfer
Restricted Securities, cooperate with the Holders to facilitate the timely preparation and delivery of certificates representing Transfer Restricted Securities to be sold and not bearing any restrictive legends; and to register such Transfer
Restricted Securities in such denominations and such names as the selling Holders may request at least two Business Days prior to such sale of Transfer Restricted Securities; 
  
 (xiv) use their reasonable best efforts to cause the disposition of the Transfer Restricted Securities
covered by the Registration Statement to be registered with or approved by such other governmental agencies or authorities as may be necessary to enable the seller or sellers thereof to consummate the disposition of such Transfer Restricted
Securities, subject to the proviso contained in clause (xii) above; 
  
 (xv) provide a CUSIP number for all Transfer Restricted Securities not later than the effective date of a Registration Statement covering such Transfer Restricted Securities and provide the Trustee under the Indenture
with printed certificates for the Transfer Restricted Securities which are in a form eligible for deposit with the Depository Trust Company; 
  
 (xvi) otherwise use their respective reasonable best efforts to comply with all applicable rules and regulations of the Commission, and
make generally 

  

 12 

 
available to their security holders with regard to any applicable Registration Statement, as soon as practicable, a consolidated earnings statement meeting
the requirements of Rule 158 (which need not be audited) covering a twelve-month period beginning after the effective date of the Registration Statement (as such term is defined in paragraph (c) of Rule 158 under the Act); 
  
 (xvii) cause the Indenture to be qualified under the TIA not
later than the effective date of the first Registration Statement required by this Agreement and, in connection therewith, cooperate with the Trustee and the Holders to effect such changes to the Indenture as may be required for such Indenture to be
so qualified in accordance with the terms of the TIA; and execute and use their best efforts to cause the Trustee to execute, all documents that may be required to effect such changes and all other forms and documents required to be filed with the
Commission to enable such Indenture to be so qualified in a timely manner; and 
  
 (xviii) provide promptly to each Holder, upon request, each document filed with the Commission pursuant to the requirements of Section 13
or Section 15(d) of the Exchange Act. 
  
 (d) Restrictions on
Holders. Each Holder agrees by acquisition of a Transfer Restricted Security that, upon receipt of the notice referred to in Section 6(c)(iii)(C) or any notice from the Issuers of the existence of any fact of the kind described in Section
6(c)(iii)(D) hereof (in each case, a “Suspension Notice”), such Holder will forthwith discontinue disposition of Transfer Restricted Securities pursuant to the applicable Registration Statement until (i) such Holder has
received copies of the supplemented or amended Prospectus contemplated by Section 6(c)(iv) hereof, or (ii) such Holder is advised in writing by the Issuers that the use of the Prospectus may be resumed, and has received copies of any additional or
supplemental filings that are incorporated by reference in the Prospectus (in each case, the “Recommencement Date”). Each Holder receiving a Suspension Notice hereby agrees that it will either (i) destroy any Prospectuses,
other than permanent file copies, then in such Holder’s possession which have been replaced by the Issuers with more recently dated Prospectuses or (ii) deliver to the Issuers (at the Issuers’ expense) all copies, other than permanent file
copies, then in such Holder’s possession of the Prospectus covering such Transfer Restricted Securities that was current at the time of receipt of the Suspension Notice. The time period regarding the effectiveness of such Registration Statement
set forth in Section 3 or 4 hereof, as applicable, shall be extended by a number of days equal to the number of days in the period from and including the date of delivery of the Suspension Notice to the date of delivery of the Recommencement Date.

  

	7.	REGISTRATION EXPENSES 

  
 (a) All expenses incident to the Issuers’ performance of or compliance with this Agreement will be borne by the Issuers, regardless of whether a
Registration Statement becomes effective, including without limitation: (i) all registration and filing fees and expenses; (ii) all fees and expenses of compliance with federal securities and state Blue Sky or securities laws; (iii) all expenses of
printing (including printing certificates for the Series B Notes to be issued in the Exchange Offer and printing of Prospectuses), messenger and delivery services and telephone; (iv) all fees and disbursements of counsel for the Issuers; (v) all
application and filing fees in connection with listing the Series B Notes on a national securities exchange or automated 

  

 13 

 
quotation system; and (vi) all fees and disbursements of independent certified public accountants of the Issuers (including the expenses of any special audit
and comfort letters required by or incident to such performance). 
  
 The Issuers will, in any event, bear their internal expenses (including, without limitation, all salaries and expenses of its officers and employees performing legal or accounting duties), the expenses of any annual audit and the fees and
expenses of any Person, including special experts, retained by the Issuers. 
  
 (b) In connection with any Registration Statement required by this Agreement (including, without limitation, the Exchange Offer Registration Statement and the Shelf Registration Statement), the Issuers will reimburse
the Initial Purchasers and the Holders of Transfer Restricted Securities who are tendering Series A Notes into in the Exchange Offer and/or selling or reselling Series A Notes or Series B Notes pursuant to the “Plan of Distribution”
contained in the Exchange Offer Registration Statement or the Shelf Registration Statement, as applicable, for the reasonable fees and disbursements of not more than one counsel, who shall be Latham & Watkins, unless another firm shall be chosen
by the Holders of a majority in principal amount of the Transfer Restricted Securities for whose benefit such Registration Statement is being prepared. 
  

	8.	INDEMNIFICATION 

  
 (a) Each of the Issuers agrees, jointly and severally, to indemnify and hold harmless each Holder, its directors, officers and each Person, if any, who
controls such Holder (within the meaning of Section 15 of the Act or Section 20 of the Exchange Act), from and
against any and all losses, claims, damages, liabilities and judgments (including, without limitation, any legal or other expenses incurred in connection with investigating or defending any matter, including any action, that could give rise to any
such losses, claims, damages, liabilities or judgments) caused by any untrue statement or alleged untrue statement of a material fact contained in any Registration Statement, preliminary prospectus or Prospectus (or any amendment or supplement
thereto) provided by the Issuers to any Holder or any prospective purchaser of Series B Notes or registered Series A Notes, or caused by any omission or alleged omission to state therein a material fact required to be stated therein or necessary to
make the statements therein not misleading, except insofar as such losses, claims, damages, liabilities or judgments are caused by an untrue statement or omission or alleged untrue statement or omission that is based upon information relating to any
of the Holders furnished in writing to the Issuers by any of the Holders; provided that the indemnity provided for in this paragraph shall not apply to any Holder who failed to deliver a Prospectus to any prospective purchaser of Series B Notes or
registered Series A Notes.  
  
 (b) Each Holder of Transfer
Restricted Securities agrees, severally and not jointly, to indemnify and hold harmless the Issuers, and their respective directors and officers, and each person, if any, who controls (within the meaning of Section 15 of the Act or Section 20 of the
Exchange Act) the Issuers to the same extent as the foregoing indemnity from the Issuers set forth in paragraph (a) above, but only with reference to information relating to such Holder furnished in writing to the Issuers by such Holder expressly
for use in any Registration Statement. In no event shall any Holder, its directors, officers or any Person who controls such Holder be liable or responsible for any amount in excess of the amount by which the total amount received by such Holder
with respect to its sale of Transfer Restricted Securities pursuant to a Registration 

  

 14 

 
Statement exceeds (i) the amount paid by such Holder for such Transfer Restricted Securities and (ii) the amount of any damages that such Holder, its
directors, officers or any Person who controls such Holder has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission. 
  
 (c) In case any action shall be commenced involving any person in respect of which indemnity may be sought pursuant to
Section 8(a) or 8(b) (the “indemnified party”), the indemnified party shall promptly notify the person against whom such indemnity may be sought (the “indemnifying person”) in writing and the
indemnifying party shall assume the defense of such action, including the employment of counsel reasonably satisfactory to the indemnified party and the payment of all fees and expenses of such counsel, as incurred (except that in the case of any
action in respect of which indemnity may be sought pursuant to both Sections 8(a) and 8(b) above, a Holder shall not be required to assume the defense of such action pursuant to this Section 8(c), but may employ separate counsel and participate in
the defense thereof, but the fees and expenses of such counsel, except as provided below, shall be at the expense of the Holder). Any indemnified party shall have the right to employ separate counsel in any such action and participate in the defense
thereof, but the fees and expenses of such counsel shall be at the expense of the indemnified party unless (i) the employment of such counsel shall have been specifically authorized in writing by the indemnifying party, (ii) the indemnifying party
shall have failed to assume the defense of such action or employ counsel reasonably satisfactory to the indemnified party or (iii) the named parties to any such action (including any impleaded parties) include both the indemnified party and the
indemnifying party, and the indemnified party shall have been advised by such counsel that there may be one or more legal defenses available to it which are different from or additional to those available to the indemnifying party (in which case the
indemnifying party shall not have the right to assume the defense of such action on behalf of the indemnified party). In any such case, the indemnifying party shall not, in connection with any one action or separate but substantially similar or
related actions in the same jurisdiction arising out of the same general allegations or circumstances, be liable for the fees and expenses of more than one separate firm of attorneys (in addition to any local counsel) for all indemnified parties and
all such fees and expenses shall be reimbursed as they are incurred. Such firm shall be designated in writing by a majority of the Holders, in the case of the parties indemnified pursuant to Section 8(a) above, and by the Company, in the case of
parties indemnified pursuant to Section 8(b) above. The indemnifying party shall indemnify and hold harmless the indemnified party from and against any and all losses, claims, damages, liabilities and judgments by reason of any settlement of any
action (i) effected with its written consent or (ii) effected without its written consent if the settlement is entered into more than twenty business days after the indemnifying party shall have received a request from the indemnified party for
reimbursement for the fees and expenses of counsel (in any case where such fees and expenses are at the expense of the indemnifying party) and, prior to the date of such settlement, the indemnifying party shall have failed to comply with such
reimbursement request. No indemnifying party shall, without the prior written consent of the indemnified party, effect any settlement or compromise of, or consent to the entry of judgment with respect to, any pending or threatened action in respect
of which the indemnified party is or could have been a party and indemnity or contribution may be or could have been sought hereunder by the indemnified party, unless such settlement, compromise or judgment (i) includes an unconditional release of
the indemnified party from all liability on claims that are or could have been the subject matter of such action and (ii) does not include a statement as to or an admission of fault, culpability or a failure to act, by or on behalf of the
indemnified party. 
  

 15 

 (d) To the extent that the indemnification provided for in this Section 8 is unavailable to an
indemnified party in respect of any losses, claims, damages, liabilities or judgments referred to herein, then each indemnifying party, in lieu of indemnifying such indemnified party, shall contribute to the amount paid or payable by such
indemnified party as a result of such losses, claims, damages, liabilities or judgments (i) in such proportion as is appropriate to reflect the relative benefits received by the Issuers, on the one hand, and the Holders, on the other hand, from
their sale of Transfer Restricted Securities or (ii) if the allocation provided by clause 8(d)(i) is not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative benefits referred to in clause 8(d)(i) above
but also the relative fault of the Issuers, on the one hand, and of the Holders, on the other hand, in connection with the statements or omissions which resulted in such losses, claims, damages, liabilities or judgments, as well as any other
relevant equitable considerations. The relative fault of the Issuers, on the one hand, and of the Holders, on the other hand, shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact
or the omission or alleged omission to state a material fact relates to information supplied by the Issuers, on the one hand, or by the Holders, on the other hand, and the parties’ relative intent, knowledge, access to information and
opportunity to correct or prevent such statement or omission. The amount paid or payable by a party as a result of the losses, claims, damages, liabilities and judgments referred to above shall be deemed to include, subject to the limitations set
forth in Section 8(a) above, any legal or other fees or expenses reasonably incurred by such party in connection with investigating or defending any action or claim. 
  
 The Issuers and each Holder agree that it would not be just and equitable if contribution pursuant to this Section 8(d) were
determined by pro rata allocation (even if the Holders were treated as one entity for such purpose) or by any other method of allocation which does not take account of the equitable considerations referred to in the immediately preceding paragraph.
The amount paid or payable by an indemnified party as a result of the losses, claims, damages, liabilities or judgments referred to in the immediately preceding paragraph shall be deemed to include, subject to the limitations set forth above, any
legal or other expenses reasonably incurred by such indemnified party in connection with investigating or defending any matter, including any action that could have given rise to such losses, claims, damages, liabilities or judgments.
Notwithstanding the provisions of this Section 8, no Holder, its directors, its officers or any Person, if any, who controls such Holder shall be required to contribute, in the aggregate, any amount in excess of the amount by which the total
received by such Holder with respect to the sale of Transfer Restricted Securities pursuant to a Registration Statement exceeds (i) the amount paid by such Holder for such Transfer Restricted Securities and (ii) the amount of any damages which such
Holder has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission. No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Act) shall be entitled to
contribution from any person who was not guilty of such fraudulent misrepresentation. The Holders’ obligations to contribute pursuant to this Section 8(c) are several in proportion to the respective principal amount of Transfer Restricted
Securities held by each Holder hereunder and not joint. 
  

	9.	RULE 144A AND RULE 144 

  
 The Issuers agree with each Holder, for so long as any Transfer Restricted Securities remain outstanding and during any period in which the Issuers (i)
are not subject to Section 13 or 15(d) of the Exchange Act, to make available, upon request of any Holder, to such Holder or 

  

 16 

 
beneficial owner of Transfer Restricted Securities in connection with any sale thereof and any prospective purchaser of such Transfer Restricted Securities
designated by such Holder or beneficial owner, the information required by Rule 144A(d)(4) under the Act in order to permit resales of such Transfer Restricted Securities pursuant to Rule 144A, and (ii) are subject to Section 13 or 15(d) of the
Exchange Act, to make all filings required thereby in a timely manner in order to permit resales of such Transfer Restricted Securities pursuant to Rule 144. 
  

	10.	MISCELLANEOUS 

  
 (a) Remedies. The Issuers acknowledge and agree that any failure by the Issuers to comply with their obligations under Sections 3 and 4 hereof may
result in material irreparable injury to the Initial Purchasers or the Holders for which there is no adequate remedy at law, that it will not be possible to measure damages for such injuries precisely and that, in the event of any such failure, the
Initial Purchasers or any Holder may obtain such relief as may be required to specifically enforce the Issuers’ obligations under Sections 3 and 4 hereof. The Issuers further agree to waive the defense in any action for specific performance
that a remedy at law would be adequate. 
  
 (b) No Inconsistent
Agreements. Neither Issuer will, on or after the date of this Agreement, enter into any agreement with respect to its securities that is inconsistent with the rights granted to the Holders in this Agreement or otherwise conflicts with the
provisions hereof. Neither Issuer has previously entered into any agreement granting any registration rights with respect to its securities to any Person. The rights granted to the Holders hereunder do not in any way conflict with and are not
inconsistent with the rights granted to the holders of either Issuer’s securities under any agreement in effect on the date hereof. 
  
 (c) Amendments and Waivers. The provisions of this Agreement may not be amended, modified or supplemented, and waivers or consents to or departures
from the provisions hereof may not be given unless (i) in the case of Section 5 hereof and this Section 10(c)(i), the Issuers have obtained the written consent of Holders of all outstanding Transfer Restricted Securities and (ii) in the case of all
other provisions hereof, the Issuers have obtained the written consent of Holders of a majority of the outstanding principal amount of Transfer Restricted Securities (excluding Transfer Restricted Securities held by the Issuers or their Affiliates).
Notwithstanding the foregoing, a waiver or consent to departure from the provisions hereof that relates exclusively to the rights of Holders whose Transfer Restricted Securities are being tendered pursuant to the Exchange Offer, and that does not
affect directly or indirectly the rights of other Holders whose Transfer Restricted Securities are not being tendered pursuant to such Exchange Offer, may be given by the Holders of a majority of the outstanding principal amount of Transfer
Restricted Securities subject to such Exchange Offer. 
  
 (d)
Third Party Beneficiary. The Holders shall be third party beneficiaries to the agreements made hereunder between the Issuers, on the one hand, and the Initial Purchasers, on the other hand, and shall have the right to enforce such agreements
directly to the extent they may deem such enforcement necessary or advisable to protect their rights or the rights of Holders hereunder. 
  

 17 

 (e) Notices. All notices and other communications provided for or permitted hereunder shall be
made in writing by hand-delivery, first-class mail (registered or certified, return receipt requested), telex, telecopier, or air courier guaranteeing overnight delivery: 
  
 (i) if to a Holder, at the address set forth on the records of the Registrar under the Indenture, with a
copy to the Registrar under the Indenture; and 
  
 (ii) if to the Issuers: 
  
 Insight
Midwest, L.P. 
 Insight Capital, Inc. 
 810 Seventh Avenue 
 41st Floor 
 New York, NY 10019 
 Telecopier No.: (917) 286-2301 
 Attention: Elliot Brecher, Esq. 
  
 With a copy to: 
  
 Sonnenschein Nath & Rosenthal LLP 
 1221 Avenue of the Americas 
 New York, NY 10020 
 Telecopier No.: (212) 768-6800 
 Attention: Robert Winikoff, Esq. 
  
 All such notices and communications shall be deemed to have been duly given:
at the time delivered by hand, if personally delivered; five Business Days after being deposited in the mail, postage prepaid, if mailed; when receipt acknowledged, if telecopied; and on the next business day, if timely delivered to an air courier
guaranteeing overnight delivery. 
  
 Copies of all such notices,
demands or other communications shall be concurrently delivered by the Person giving the same to the Trustee at the address specified in the Indenture. 
  
 (f) Successors and Assigns. This Agreement shall inure to the benefit of and be binding upon the successors and assigns of each of the parties,
including without limitation and without the need for an express assignment, subsequent Holders; provided, that nothing herein shall be deemed to permit any assignment, transfer or other disposition of Transfer Restricted Securities in
violation of the terms hereof or of the Purchase Agreement or the Indenture. If any transferee of any Holder shall acquire Transfer Restricted Securities in any manner, whether by operation of law or otherwise, such Transfer Restricted Securities
shall be held subject to all of the terms of this Agreement, and by taking and holding such Transfer Restricted Securities such Person shall be conclusively deemed to have agreed to be bound by and to perform all of the terms and provisions of this
Agreement, including the restrictions on resale set forth in this Agreement and, if applicable, the Purchase Agreement, and such Person shall be entitled to receive the benefits hereof. 
  
 (g) Counterparts. This Agreement may be executed in any number of counterparts and by the parties hereto in separate
counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute one and the same agreement. 
  
 (h) Headings. The headings in this Agreement are for convenience of reference only and shall not limit or otherwise affect the meaning hereof.

  

 18 

 (i) Governing Law. THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS
OF THE STATE OF NEW YORK, WITHOUT REGARD TO THE CONFLICT OF LAW RULES THEREOF. 
  
 (j) Severability. In the event that any one or more of the provisions contained herein, or the application thereof in any circumstance, is held invalid, illegal or unenforceable, the validity, legality and
enforceability of any such provision in every other respect and of the remaining provisions contained herein shall not be affected or impaired thereby. 
  
 (k) Entire Agreement. This Agreement is intended by the parties as a final expression of their agreement and intended to be a complete and
exclusive statement of the agreement and understanding of the parties hereto in respect of the subject matter contained herein. There are no restrictions, promises, warranties or undertakings, other than those set forth or referred to herein with
respect to the registration rights granted with respect to the Transfer Restricted Securities. This Agreement supersedes all prior agreements and understandings between the parties with respect to such subject matter. 
  
 [signature page follows] 
  

 19 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	INSIGHT MIDWEST, L.P.
		
	By:	 	/s/    ELLIOT BRECHER        
	 	 	

	 	 	 Name:

	 	 	 Title:

  

			
	 INSIGHT CAPITAL, INC.

		
	By:	 	/s/    ELLIOT BRECHER        
	 	 	

	 	 	 Name:

	 	 	 Title:

  

			
	 BANC OF AMERICA SECURITIES LLC
 BNY CAPITAL
MARKETS, INC.
 J.P. MORGAN SECURITIES INC.
 MORGAN STANLEY &
CO. INCORPORATED
 TD SECURITIES (USA) INC.

	  
 By: BANC OF AMERICA SECURITIES LLC

		
	By:	 	 /s/    

	 	 	

	 	 	 Name:

	 	 	 Title:

  

 20

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00067-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00067-of-00352.parquet"}]]